Assessment of genetically modified maize MON 87427&#160;&#215; MON 87460&#160;&#215;&#160;MON 89034&#160;&#215;&#160;MIR162&#160;&#215;&#160;NK603 and subcombinations, for food and feed uses, under Regulation (EC) No&#160;1829/2003 (application EFSA-GMO-NL-2016-134) by H. Naegeli et al.
SCIENTIFIC OPINION
ADOPTED: 3 July 2019
doi: 10.2903/j.efsa.2019.5774
Assessment of genetically modified maize MON 87427 3
MON 87460 3 MON 89034 3 MIR162 3 NK603 and
subcombinations, for food and feed uses, under Regulation
(EC) No 1829/2003 (application EFSA-GMO-NL-2016-134)
EFSA Panel on Genetically Modified Organisms (GMO),
Hanspeter Naegeli, Jean-Louis Bresson, Tamas Dalmay, Ian Crawford Dewhurst,
Michelle M Epstein, Leslie George Firbank, Philippe Guerche, Jan Hejatko,
Francisco Javier Moreno, Ewen Mullins, Fabien Nogue, Nils Rostoks, Jose Juan Sanchez Serrano,
Giovanni Savoini, Eve Veromann, Fabio Veronesi, Fernando Alvarez, Michele Ardizzone,
Giacomo De Sanctis, Antonio Fernandez Dumont, Andrea Gennaro, Jose Angel Gomez Ruiz,
Anna Lanzoni, Nikoletta Papadopoulou and Konstantinos Paraskevopoulos
Abstract
Maize MON 87427 9MON 87460 9 MON 89034 9 MIR162 9 NK603 (five-event stack maize) was
produced by conventional crossing to combine five single events: MON 87427, MON 87460,
MON 89034, MIR162 and NK603. The GMO Panel previously assessed the five single maize events and
eleven of the subcombinations and did not identify safety concerns. No new data on the single maize
events or the 11 subcombinations that could lead to modification of the original conclusions on their
safety were identified. The molecular characterisation, comparative analysis (agronomic, phenotypic
and compositional characteristics) and the outcome of the toxicological, allergenicity and nutritional
assessment indicate that the combination of the single maize events and of the newly expressed
proteins in the five-event stack maize does not give rise to food and feed safety and nutritional
concerns. The GMO Panel concludes that the five-event stack maize, as described in this application, is
as safe as and nutritionally equivalent to its non-GM comparator and the non-GM reference varieties
tested. In the case of accidental release of viable grains of the five-event stack maize into the
environment, this would not raise environmental safety concerns. The GMO Panel assessed the
likelihood of interactions among the single events in the 14 maize subcombinations not previously
assessed and concludes that these are expected to be as safe as and nutritionally equivalent to the
single events, the previously assessed subcombinations and the five-event stack maize. The post-
market environmental monitoring plan and reporting intervals are in line with the intended uses of the
five-event stack maize. Post-market monitoring of food/feed is not considered necessary. The GMO
Panel concludes that the five-event stack maize and its subcombinations are as safe as its non-GM
comparator and the tested non-GM reference varieties with respect to potential effects on human and
animal health and the environment.
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Summary
Following the submission of application EFSA-GMO-NL-2016-134 under Regulation (EC) No 1829/2003
from Monsanto Company (referred to hereafter as the applicant), the Panel on Genetically Modified
Organisms of the European Food Safety Authority (referred to hereafter as GMO Panel) was asked to
deliver a Scientific Opinion on the safety of genetically modified drought- and glyphosate-tolerant and
insect resistant maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 (referred to
hereafter as ‘five-event stack maize’) and its subcombinations independently of their origin, according to
the Commission Regulation (EU) No 503/2013 (referred to hereafter as ‘subcombinations’). The scope of
application EFSA–GMO–NL–2016–134 is for the placing on the market of maize MON 87427 9
MON 87460 9 MON 89034 9 MIR162 9 NK603 and all its subcombinations independently of their
origin for food and feed uses, import and processing.
The term ‘subcombination’ refers to any combination of up to four of the events present in the five-
event stack maize. The safety of subcombinations occurring as segregating progeny in the harvested
grains of maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 is evaluated in the
context of the assessment of the five-event stack maize. The safety of subcombinations that have
either been, or could be produced by conventional crossing through targeted breeding approaches,
and which can be bred, produced and marketed independently of the five-event stack, are risk
assessed separately in the present scientific opinion.
The five-event stack maize was produced by conventional crossing to combine five single maize
events: MON 87427 (expressing the 5-enolpyruvylshikimate-3-phosphate synthase (CP4 EPSPS)
protein); MON 87460 (expressing the cold shock protein B (CSPB) and neomycin phosphotransferase II
protein (NPTII)); MON 89034 (expressing the Cry1A.105 and Cry2Ab2 proteins); MIR162 (expressing
the Vip3Aa20 and phosphomannose isomerase (PMI) proteins)); and NK603 (expressing the CP4
EPSPS protein and the variant CP4 EPSPS L214P) to confer resistance to certain lepidopteran pests and
tolerance to drought and glyphosate-containing herbicides.
The GMO Panel evaluated the five-event stack maize and its subcombinations with reference to the
scope and appropriate principles described in its guidelines for the risk assessment of GM plants and
derived food and feed, the environmental risk assessment of GM plants and the post-market
environmental monitoring of GM plants. The GMO Panel considered the information submitted in
application EFSA-GMO-NL-2016-134, additional information provided by the applicant during the risk
assessment, the scientific comments submitted by the Member States and the relevant scientific
literature.
The previous assessments of the single events MON 87427, MON 87460, MON 89034, MIR162,
NK603 and eleven of the subcombinations provided a basis for the assessment of the five-event stack
maize and the remaining 14 subcombinations. No safety concerns were identified by the GMO Panel in
the previous assessments. No safety issue concerning the five single maize events was identified by
the updated bioinformatic analyses, nor reported by the applicant since the publication of the previous
GMO Panel scientific opinions. Therefore, the GMO Panel considers that its previous conclusions on the
safety of the single maize events remain valid.
For the five-event stack maize, the risk assessment included the molecular characterisation of the
inserted DNA and analysis of protein expression. An evaluation of the comparative analysis of
agronomic/phenotypic and compositional characteristics was undertaken, and the safety of the newly
expressed proteins and the whole food and feed were evaluated with respect to potential toxicity,
allergenicity and nutritional characteristics. An evaluation of environmental impacts and the post-
market environmental monitoring (PMEM) plan was also undertaken.
The molecular data establish that the events stacked in maize MON 87427 9 MON 87460 9
MON 89034 9 MIR162 9 NK603 have retained their integrity. Protein expression analyses showed that
the levels of the newly expressed proteins are similar in the five-event stack maize and in the single
events, except for the expected difference for the CP4 EPSPS protein levels resulting from the
combination of the MON 87427 and NK603 single events, both producing CP4 EPSPS protein in
the five-event stack. No indications of interactions that may affect the integrity of the events and the
levels of the newly expressed proteins in this five-event stack maize were identified.
The comparative analysis of forage and grain composition and agronomic/phenotypic characteristics
identified no differences between maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603
and the non-GM comparator that required further assessment for food/feed safety or environmental
impact.
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The molecular characterisation, the comparative analysis and the outcome of the toxicological,
allergenicity and nutritional assessment indicate that the combination of the single maize events and of
the newly expressed proteins in the five-event stack maize does not give rise to food and feed safety
and nutritional concerns. The GMO Panel concludes that maize MON 87427 9 MON 87460
9 MON 89034 9 MIR162 9 NK603, as described in this application, is as safe as and nutritionally
equivalent to its non-GM comparator and the non-GM reference varieties tested.
Considering the combined events and their potential interactions, the outcome of the comparative
analysis, and the routes and levels of exposure, the GMO Panel concludes that maize
MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 would not raise safety concerns in the
case of accidental release of viable GM maize grains into the environment.
Since no new safety concerns were identified for the eleven previously assessed subcombinations,
and no new data leading to the modification of the original conclusions on safety were identified, the
GMO Panel considers that its previous conclusions on these maize subcombinations remain valid. For
the remaining 14 subcombinations included in the scope of application EFSA-GMO-NL-2016-134, no
experimental data were provided. The GMO Panel assessed the possibility of interactions between the
events in the 14 subcombinations and concludes that these subcombinations would not raise safety
concerns. These subcombinations are therefore expected to be as safe as and nutritionally equivalent
to the single events, the previously assessed subcombinations and the five-event stack maize.
Based on the relevant publications identified through the literature searches, the GMO Panel does not
identify any safety issue pertaining to the intended uses of maize MON 87427 9 MON 87460 9
MON 89034 9 MIR162 9 NK603 and its subcombinations. In the context of annual PMEM reports, the
applicant could further fine–tune future literature searches according to the GMO
Panel recommendations given in this scientific opinion.
Given the absence of safety concerns for foods and feeds from maize MON 87427 9 MON 87460 9
MON 89034 9 MIR162 9 NK603 and its subcombinations, the GMO Panel considers that post-market
monitoring of these products is not necessary. The post-market environmental monitoring plan and
reporting intervals are in line with the intended uses of the five-event stack maize and its
subcombinations.
The GMO Panel concludes that maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9
NK603 and its subcombinations, as described in this application, are as safe as the non-GM
comparator and the tested non-GM reference varieties with respect to potential effects on human and
animal health and the environment.
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1. Introduction
The scope of application EFSA-GMO-NL-2016-134 is for food and feed uses, import and processing
in the European Union (EU) of the genetically modified (GM) herbicide- and drought-tolerant and
insect-resistant maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 and all its
subcombinations independently of their origin.
1.1. Background
On 30 November 2016, the European Food Safety Authority (EFSA) received from the Competent
Authority of The Netherlands application EFSA-GMO-NL-2016-134 for authorisation of maize
MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 (hereafter referred to as ‘the five-
event stack maize’) (Unique Identifier MON-87427-7 9 MON-8746Ø-4 9 MON-89Ø34-3 9 SYN-IR162-
4 9 MON-ØØ6Ø3-6), submitted by Monsanto Europe S.A. (hereafter referred to as ‘the applicant’)
according to Regulation (EC) No 1829/2003.1
Following receipt of application EFSA-GMO-NL-2016-134, EFSA informed the Member States (MS)
and the European Commission and made the summary of the application available to the public on the
EFSA website.2
EFSA checked the application for compliance with the relevant requirements of Regulation (EC)
No 1829/2003 and Regulation (EU) No 503/20133 and, when needed, asked the applicant to supplement
the initial application. On 19 January 2017, EFSA declared the application valid and made the valid
application available to MS and the EC.
From the validity date, EFSA and its scientific Panel on Genetically Modified Organisms (hereafter
referred to as ‘the GMO Panel’) endeavoured to respect a time limit of 6 months to issue a scientific
opinion on application EFSA-GMO-NL-2016-134. Such time limit was extended whenever EFSA and/or its
GMO Panel requested supplementary information to the applicant. According to Regulation (EC)
No 1829/2003, any supplementary information provided by the applicant during the risk assessment was
made available to the EU Member States and European Commission (for further details, see the section
‘Documentation’, below).
In accordance with Regulation (EC) No 1829/2003, EFSA consulted the nominated risk assessment
bodies of EU Member States, including national Competent Authorities within the meaning of Directive
2001/18/EC.4 The EU Member States had three months to make their opinion known on application
EFSA-GMO-NL-2016-134 as of date of validity.
1.2. Terms of Reference as provided by the requestor
According to Articles 6 and 18 of Regulation (EC) No 1829/2003, EFSA and its GMO Panel were
requested to carry out a scientific risk assessment of maize MON 87427 9 MON 87460 9 MON
89034 9 MIR162 9 NK603 and all maize subcombinations of the individual events independently of
their origin (as present in the segregating progeny as well as independent stacks to be placed on the
market as such) in the context of its scope as defined in application EFSA-GMO-NL-2016-134.
According to Regulation (EC) No 1829/2003, this scientific opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation including the opinions of the nominated risk
assessment bodies of EU Member States.5
In addition to the present scientific opinion on maize MON 87427 9 MON 87460 9 MON
89034 9 MIR162 9 NK603, EFSA and its GMO Panel were also asked to report on the particulars listed
under Articles 6(5) and 18(5) of Regulation (EC) No 1829/2003. The relevant information is made
available in the EFSA Register of Questions,6 including the information required under Annex II to the
Cartagena Protocol, a labelling proposal, a Post-Market Environmental Monitoring (PMEM) plan as
1 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modified
food and feed. OJ L 268, 18.10.2003, p. 1–23.
2 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionDocumentsLoader?question=EFSA-Q-2016-00686
3 Commission Implementing Regulation (EU) No 503/2013 of 3 April 2013 on applications for authorisation of genetically
modified food and feed in accordance with Regulation (EC) No 1829/2003 of the European Parliament and of the Council and
amending Commission Regulations (EC) No 641/2004 and (EC) No 1981/2006. OJ L157, 8.6.2013, p. 1–48.
4 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modified organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001, p. 1–38.
5 Opinions of the nominated risk assessment bodies of EU Member States can be found at the EFSA Register of Questions
(http://registerofquestions.efsa.europa.eu/roqFrontend/login), querying the assigned Question Number.
6 http://registerofquestions.efsa.europa.eu/roqFrontend/questionDocumentsLoader?question=EFSA-Q-2016-00686
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provided by the applicant; the method(s), validated by the Community reference laboratory, for
detection, including sampling, identification of the transformation event in the food-feed and/or foods-
feeds produced from it and the appropriate reference materials.
2. Data and methodologies
2.1. Data
The GMO Panel based its scientific risk assessment of maize MON 87427 9 MON 87460 9
MON 89034 9 MIR162 9 NK603 on the valid application EFSA-GMO-NL-2016-134, additional information
provided by the applicant during the risk assessment, relevant scientific comments submitted by EU
Member States and relevant peer-reviewed scientific publications. In addition to this comprehensive
information package, the GMO Panel also received unpublished studies submitted by the applicant in
order to comply with the specific provisions of Regulation (EU) No 503/2013. A list of these additional
unpublished studies is provided in Appendix B.
2.2. Methodologies
The GMO Panel conducted its assessment in line with the principles described in Regulation (EU)
No 503/2013, its applicable guidelines (i.e., EFSA GMO Panel, 2010a,b, 2011a,b, 2015a) and explanatory
notes (i.e. EFSA, 2017a,b) for the risk assessment of GM plants. During its risk assessment the GMO
Panel considered all additional unpublished studies as listed in Appendix B for potential effects of the GM
food and feed on human and animal health and the environment.
For the assessment of 90-day animal feeding studies, the GMO Panel took into account the criteria
included in the 2011 EFSA Scientific Committee guidance on conducting repeated-dose 90-day oral
toxicity study in rodents on whole food/feed (EFSA Scientific Committee, 2011) and the explanatory
statement for its applicability (EFSA, 2014).
The GMO Panel also assessed the applicant’s literature searches, which include a scoping review, in
accordance with the recommendations on literature searching outlined in EFSA (2010, 2017a).
In the frame of the contracts OC/EFSA/GMO/2013/01 and OC/EFSA/GMO/2014/01, contractors
performed preparatory work and delivered reports on the methods applied by the applicant in
performing bioinformatic and statistical analyses, respectively.
3. Assessment
3.1. Introduction
Application EFSA-GMO-NL-2016-134 covers the five-event stack maize MON 87427 9 MON
87460 9 MON 89034 9 MIR162 9 NK603 and all its 25 subcombinations independently of their origin
(Table 1). The scope of this application is for food and feed uses, import and processing, and excludes
cultivation within the European Union (EU).
Table 1: Stacked maize events covered by the scope of application EFSA-GMO-NL-2016-134
Degree of
stacking
Event Unique identifier
Five-event
stack maize
MON 87427 9 MON 87460 9 MON
89034 9 MIR162 9 NK603
MON–87427–7 9 MON 8746Ø 9 MON–89Ø34–
3 9 SYN-IR162-4 9 MON–ØØ6Ø3–6
Four-event
stack maize
MON 87460 9 MON
89034 9 MIR162 9 NK603
MON 8746Ø 9 MON–89Ø34–3 9 SYN-IR162-
4 9 MON–ØØ6Ø3–6
MON 87427 9 MON
89034 9 MIR162 9 NK603
MON–87427–7 9 MON–89Ø34–3 9 SYN-IR162-
4 9 MON–ØØ6Ø3–6
MON 87427 9 MON
87460 9 MIR162 9 NK603
MON–87427–7 9 MON 8746Ø 9 SYN-IR162-
4 9 MON–ØØ6Ø3–6
MON 87427 9 MON 87460 9 MON
89034 9 NK603
MON–87427–7 9 MON 8746Ø 9 MON–89Ø34–
3 9 MON–ØØ6Ø3–6
MON 87427 9 MON 87460 9 MON
89034 9 MIR162
MON–87427–7 9 MON 8746Ø 9 MON–89Ø34–
3 9 SYN-IR162-4
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The term ‘subcombination’ refers to any combination of up to four of the events present in the five-
event stack maize.
The safety of subcombinations occurring as segregating progeny in the harvested grains of maize
MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 is evaluated in the context of the
assessment of the five-event stack maize in Section 3.4 of the present scientific opinion.
‘Subcombination’ also covers combinations that have either been, or could be produced by
conventional crossing through targeted breeding approaches (EFSA GMO Panel, 2011a). These are
maize stacks that can be bred, produced and marketed independently of the five-event stack maize.
These subcombinations are risk assessed in the Section 3.5 of this scientific opinion.
The five-event stack maize was produced by conventional crossing to combine five single maize
events: MON 87427 (expressing the 5-enolpyruvylshikimate-3-phosphate synthase (CP4 EPSPS)
protein); MON 87460 (expressing the cold shock protein B (CSPB) and Neomycin phosphotransferase
II protein (NPTII)); MON 89034 (expressing the Cry1A.105 and Cry2Ab2 proteins); MIR162
(expressing the Vip3Aa20 and phosphomannose isomerase (PMI) proteins)); and NK603 (expressing
the CP4 EPSPS protein and the variant CP4 EPSPS L214P) to confer resistance to certain lepidopteran
pests and tolerance to drought and glyphosate-containing herbicides. It should be noted that the
assessment of herbicide residues relevant for this application has been investigated by the EFSA
Pesticides Unit (EFSA, 2018).
All five single maize events, the two-event stack MON 89034 9 NK603, the three-event stack maize
MON 87427 9 MON 89034 9 NK603 and all its subcombinations as well as the four-event stack maize
MON 87427 9 MON 89034 9 MIR162 9 NK603 and all its subcombinations independently of their
origin have been previously assessed by the GMO Panel (see Table 2), and no safety concerns were
identified.
Degree of
stacking
Event Unique identifier
Three-event
stack maize
MON 87427 9 MON 87460 9 MON 89034 MON–87427–7 9 MON 8746Ø 9 MON–89Ø34–3
MON 87427 9 MON 87460 9 MIR162 MON–87427–7 9 MON 8746Ø 9 SYN-IR162-4
MON 87427 9 MON 87460 9 NK603 MON–87427–7 9 MON 8746Ø 9 MON–ØØ6Ø3–6
MON 87427 9 MON 89034 9 NK603 MON–87427–7 9 MON–89Ø34–3 9 MON–ØØ6Ø3–6
MON 87427 9 MIR162 9 NK603 MON–87427–7 9 SYN-IR162-4 9 MON–ØØ6Ø3–6
MON 87427 9 MON 89034 9 MIR162 MON–87427–7 9 MON–89Ø34–3 9 SYN-IR162-4
MON 87460 9 MON 89034 9 MIR162 MON–87427–7 9 MON–89Ø34–3 9 SYN-IR162-4
MON 87460 9 MON 89034 9 NK603 MON 8746Ø 9 MON–89Ø34–3 9 MON–ØØ6Ø3–6
MON 87460 9 MIR162 9 NK603 MON 8746Ø 9 SYN-IR162-4 9 MON–ØØ6Ø3–6
MON 89034 9 MIR162 9 NK603 MON–89Ø34–3 9 SYN-IR162-4 9 MON–ØØ6Ø3–6
Two-event
stack maize
MON 87427 9 MON 89034 MON–87427–7 9 MON–89Ø34–3
MON 87427 9 MON 87460 MON–87427–7 9 MON 8746Ø
MON 87427 9 NK603 MON–87427–7 9 MON–ØØ6Ø3–6
MON 87427 9 MIR162 MON–87427–7 9 SYN-IR162-4
MON 87460 9 MON 89034 MON 8746Ø 9 MON–89Ø34–3
MON 87460 9 MIR162 MON 8746Ø 9 SYN-IR162-4
MON 87460 9 NK 603 MON 8746Ø 9 MON–ØØ6Ø3–6
MON 89034 9 NK603 MON–89Ø34–3 9 MON–ØØ6Ø3–6
MON 89034 9 MIR162 MON–89Ø34–3 9 SYN-IR162-4
MIR162 9 NK603 SYN-IR162-4 9 MON–ØØ6Ø3–6
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3.2. Updated information on the single events7
Since the publication of the scientific opinions on the single maize events by the GMO Panel (see
Table 2), no safety issue concerning the five single events has been reported by the applicant.
Updated bioinformatic analyses for maize events MON 87427, MON 87460, MON 89034, MIR162
and NK603, confirm that no known endogenous genes were disrupted by any of the inserts.
Updated bioinformatic analyses of the amino acid sequence of the newly expressed CP4 EPSPS,
CSPB, NPTII, Cry1A.105, Cry2Ab2, Vip3Aa20 and PMI proteins confirmed previous results indicating no
significant similarities to toxins or allergens. Updated bioinformatics analyses of the newly created
open reading frames (ORFs) within the inserts or spanning the junctions between the insert and the
flanking regions for events MON 87427, MON 87460, MON 89034, MIR162 and NK603 confirmed
previous analyses (Table 2). These analyses indicate that the production of a new peptide showing
significant similarities to toxins or allergens for any of the events in maize MON 87427 9 MON
87460 9 MON 89034 9 MIR162 9 NK603 is highly unlikely.
In order to assess the possibility for horizontal gene transfer (HGT) by homologous recombination
(HR), the applicant performed a sequence identity analysis to microbial DNA for events MON 87427,
MON 87460, MON 89034, MIR162 and NK603. The likelihood and potential consequences of plant-to-
bacteria gene transfer are described in Section 3.4.4.2.
Based on the above information, the GMO Panel considers that its previous conclusions on the
safety of the single maize events remain valid.
3.3. Systematic literature review8
The GMO Panel assessed the applicant’s literature searches on maize MON 87427 9 MON
87460 9 MON 89034 9 MIR162 9 NK603, which include a scoping review, according to the guidelines
given in EFSA (2010, 2017a).
A systematic review as referred to in Regulation (EU) No 503/2013 has not been provided in
support to the risk assessment of application EFSA-GMO-NL-2016-134. Based on the outcome of the
scoping review, the GMO Panel agrees that there is limited value of undertaking a systematic review
for maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 at present.
Although the overall quality of the performed literature searches is acceptable, the GMO
Panel considers that future searches on maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9
NK603 should be improved. The GMO Panel therefore recommends the applicant to:
• ensure that enough search term variation is used (covering possible synonyms, related terms,
acronyms, spelling variants, old and new terminology, brand and generic names, lay and
scientific terminology, common typos, translation issues);
• ensure that enough truncation is used and used consistently;
Table 2: Single maize events and subcombinations of maize MON 87427 9 MON 87460 9 MON
89034 9 MIR162 9 NK603 previously assessed by the GMO Panel
Event Application or mandate EFSA Scientific Opinion
MON 87427 EFSA-GMO-BE-2012-110 EFSA GMO Panel (2015b)
MON 87460 EFSA-GMO-NL-2009-70 EFSA GMO Panel (2012a)
MON 89034 EFSA-GMO-NL-2007-37 EFSA (2008)
MIR162 EFSA-GMO-DE-2010-82 EFSA GMO Panel (2012b)
NK603 CE/ES/00/01
EFSA-GMO-NL-2005-22
EFSA-GMO-RX-NK603
EFSA (2004, 2007)
EFSA (2009)
EFSA (2009)
MON 89034 9 NK603 EFSA-GMO-NL-2007-38 EFSA GMO Panel (2009)
MON 87427 9 MON 89034 9 NK603
and subcombinations
EFSA-GMO-BE-2013-117 EFSA GMO Panel, (2017a)
MON 87427 9 MON 89034 9 MIR162 9 NK603
and subcombinations
EFSA-GMO-NL-2016-131 EFSA GMO Panel (2019)
7 Dossier. Part II – Sections 1.2.1.3 and 1.2.2.2; additional information on 9/6/2017, 22/11/2018 and 30/4/2019.
8 Dossier. Part II – Section 1.2.1.3.; additional information on 9/6/2017, 22/11/2018 and 30/4/2019.
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None of the relevant publications identified through the literature searches reported information
pointing to safety issues associated with the intended uses of maize MON 87427 9 MON 87460 9
MON 89034 9 MIR162 9 NK603 and its subcombinations.
3.4. Risk assessment of the five-event stack maize MON 87427 3 MON
87460 3 MON 89034 3 MIR162 3 NK603
3.4.1. Molecular characterisation
In line with the requirements laid down by regulation (EU) 503/2013, the possible impact of the
combination of the events on their integrity, the expression levels of the newly expressed proteins and
the biological functions conferred by the individual inserts are considered below.
3.4.1.1. Genetic elements and their biological function
Maize events MON 87427, MON 87460, MON 89034, MIR162 and NK603 were combined by
conventional crossing to produce MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603. The
structure of the inserts introduced into maize MON 87427, MON 87460, MON 89034, MIR162 and
NK603 is described in detail in the respective EFSA scientific opinions (Table 2) and no new genetic
modifications were involved. Genetic elements in the expression cassettes of the single events are
summarised in Table 3.
Intended effects of the inserts in maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9
NK603 are summarised in Table 4.
Based on the known biological function of the newly expressed proteins (Table 4), the only
foreseen interactions at the biological level are between the Cry proteins or between the Vip3Aa20 and
the Cry proteins in susceptible insects.
Table 3: Genetic elements in the expression cassettes of the events stacked in maize MON
87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603
Event Promoter 5’ UTR Transit peptide Coding region Terminator
MON 87427 35S (CaMV) – CTP2 (Arabidopsis
thaliana)
CP4 epsps
(Agrobacterium sp.)
nos (Agrobacterium
tumefaciens)
MON 87460 act1 promoter
(Oryza sativa)
act1 leader and
intron (O. sativa)
– CSPB (Bacillus
subtilis)
3’UTR of T-tr7
(A. tumefaciens)
35S (CaMV) – – NPTII (Escherichia
coli)
nos (A. tumefaciens)
MON 89034 35S (CaMV) CAB (Triticum sp.) – cry1A.105 (Bacillus
thuringiensis)
Hsp17 (Triticum sp.)
35S (FMV) – CTP (Z. mays) cry2Ab2 (B.
thuringiensis)
nos (A. tumefaciens)
MIR162 ZmUbiInt
(Zea mays)
– – vip3Aa20 (B.
thuringiensis)
35S (CaMV)
ZmUbiInt
(Z. mays)
– – pmi (E. coli) nos (A. tumefaciens)
NK603 act1
(O. sativa)
act1 (O. sativa) CTP2 (A. thaliana) CP4 epsps
(Agrobacterium sp.)
nos (A. tumefaciens)
35S (CaMV) I-Hsp70 (Z. mays) CTP2 (A. thaliana) CP4 epsps l214p
(Agrobacterium sp.)
nos (A. tumefaciens)
CaMV: cauliflower mosaic virus; FMV: Figwort Mosaic Virus; CTP: chloroplast transit peptide.
–: when no element was specifically introduced to optimise expression.
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Table 4: Characteristics and intended effects of the events stacked in maize MON 87427 9 MON
87460 9 MON 89034 9 MIR162 9 NK603
Event Protein
Donor organism and biological
function
Intended effects in GM plant
MON
87427
CP4 EPSPS Based on a gene from Agrobacterium strain
CP4 (Barry et al., 2001). 5-enolpyruvyl-
shikimate-3-phosphate synthase (EPSPS) is
an enzyme involved in the shikimic acid
pathway for aromatic amino acid
biosynthesis in plants and microorganisms
(Herrmann, 1995)
Event MON 87427 expresses the bacterial
CP4 EPSPS protein which confers tolerance
to glyphosate-containing herbicides as it has
lower affinity towards glyphosate than the
plant endogenous enzyme
MON
87460
CSPB Based on a gene from Bacillus subtilis. The
cold shock protein B (CSPB) protein is an
RNA chaperone associated with enhanced
abiotic stress tolerance in bacteria
(Phadtare et al., 2002a,b; Castiglioni et al.,
2008)
Event MON 87460 expresses the bacterial
CSPB protein. The CspB coding sequence is
translated into the CSPB-L2V protein, which
differs from the B. subtilis CSPB protein by
one leucine-to-valine substitution at amino
acid position 2. CSPB expression helps to
reduce yield loss caused by drought stress
NPTII Based on a gene from bacterial transposon
Tn5. Neomycin phosphotransferase II
(NPTII) inactivates by phosphorylation a
range of antibiotics, including kanamycin
and neomycin (Fraley et al., 1983)
Event MON 87460 expresses the bacterial
NPTII protein. NPTII was used as a marker
to facilitate the selection process of
transformed plant cells
MON
89034
Cry1A.105 Based on genes from Bacillus thuringiensis
subsp. kurstaki and subsp. aizawai.
B. thuringiensis is an insect pathogen; its
insecticidal activity is attributed to the
expression of crystal protein (cry) genes
(Schnepf et al., 1998; Ellis et al., 2002)
Event MON 89034 expresses a modified
version of the Cry1A-type protein.
Cry1A.105 is a protein toxic to certain
lepidopteran larvae feeding on maize
Cry2Ab2 Based on a gene from Bacillus thuringiensis
subsp. kurstaki. B. thuringiensis is an insect
pathogen; its insecticidal activity is
attributed to the expression of crystal
protein (cry) genes (Schnepf et al., 1998;
Ellis et al., 2002)
Event MON 89034 expresses the Cry2Ab2
protein, a protein toxic to certain
lepidopteran larvae feeding on maize
MIR162 Vip3Aa20 Based on a gene from Bacillus thuringiensis
strain AB88 (Estruch et al., 1996). In
addition to Cry proteins, B. thuringiensis
also produces insecticidal proteins during its
vegetative growth stage. These are referred
to as vegetative insecticidal proteins (Vip)
(Fang et al., 2007)
Event MIR162 expresses a modified version
of the B. thuringiensis vip3Aa1 gene, and
encodes Vip3Aa20, a protein toxic to certain
lepidopteran larvae feeding on maize
PMI Based on a gene from E. coli. The
phosphomannose isomerase (PMI) enzyme
catalyses the isomerisation of mannose-6-
phosphate to fructose-6-phosphate and
plays a role in the metabolism of mannose
(Markovitz et al., 1967)
Event MIR162 expresses PMI, which is used
as selectable marker. Mannose normally
inhibits root growth, respiration and
germination. Transformed cells expressing
PMI are able to utilise mannose as a carbon
source (Negrotto et al., 2000)
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3.4.1.2. Integrity of the events in the five-event stack maize MON 87427 3 MON
87460 3 MON 89034 3 MIR162 3 NK6039
The genetic stability of the inserted DNA over multiple generations in the single maize events MON
87427, MON 87460, MON 89034, MIR162 and NK603 was demonstrated previously (see Table 2).
Integrity of these events in maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 was
demonstrated by polymerase chain reaction (PCR) and sequence analysis that showed that the
sequences of the events (inserts and their flanking regions) in the five-event maize stack are identical
to the sequences originally reported for the five single events, thus confirming that the integrity of
these events was maintained in the five-event stack maize.
3.4.1.3. Information on the expression of the inserts10
CP4 EPSPS, CSPB, NPTII, Cry1A.105, Cry2Ab2 Vip3Aa20 and PMI protein levels were analysed by
enzyme-linked immunosorbent assay (ELISA) in material harvested in a field trial across five locations in
the USA in the 2014 growing season. Samples analysed included leaf (V3–V4), grain (R6), root (V3–V4)
and forage (R5) both those treated and not treated with glyphosate. In order to assess the changes in
protein expression levels which may result from potential interactions between the events, protein levels
were determined for the five-event stack and the corresponding single events in different parts of the
plant.
The levels of all the newly expressed proteins in the five-event stack and the corresponding singles
were similar in all tissues, except for the expected difference in the CP4 EPSPS protein levels resulting
from the combination of single events MON 87427 and NK603 both producing CP4 EPSPS protein in
the five-event stack maize (Appendix A). Therefore, there is no indication of an interaction that may
affect the levels of the newly expressed proteins in this stack.
3.4.1.4. Conclusions of the molecular characterisation
The molecular data establish that the events stacked in maize MON 87427 9 MON 87460 9 MON
89034 9 MIR162 9 NK603 have retained their integrity. Protein expression analyses showed that the
levels of the newly expressed proteins are similar in the five-stack maize and in the single events
except for the expected higher level of CP4 EPSPS in the stack. Therefore, there is no indication of an
interaction that may affect the integrity of the events or the levels of the newly expressed proteins in
this stack.
Based on the known biological function of the newly expressed proteins, interactions at the
biological level are expected between the Cry proteins or between the Vip3Aa20 and the Cry proteins
in susceptible insects, which will be dealt with in Section 3.4.4. In addition, the potential impact of the
RNA chaperon CSPB protein on the levels of the other newly expressed proteins was assessed by
analysing the protein expression levels in the five-event stack and the respective singles. No impact of
CSPB protein on the expression levels of the other newly expressed proteins was found.
Event Protein
Donor organism and biological
function
Intended effects in GM plant
NK603 CP4 EPSPS
CP4 EPSPS
L214P
Based on a gene from Agrobacterium strain
CP4 (Barry et al., 2001). 5-enolpyruvyl-
shikimate-3-phosphate synthase (EPSPS) is
an enzyme involved in the shikimic acid
pathway for aromatic amino acid
biosynthesis in plants and microorganisms
(Herrmann, 1995)
Based on a gene from Agrobacterium strain
CP4 (Barry et al., 2001). 5-enolpyruvyl-
shikimate-3-phosphate synthase (EPSPS) is
an enzyme involved in the shikimic acid
pathway for aromatic amino acid
biosynthesis in plants and microorganisms
(Herrmann, 1995)
Event NK603 expresses the bacterial CP4
EPSPS protein which confers tolerance to
glyphosate-containing herbicides as it has
lower affinity towards glyphosate than the
plant endogenous enzyme
Event NK603 expresses also CP4 EPSPS
L214P – this variant, compared to the CP4
EPSPS protein, contains a single amino acid
substitution from leucine to proline at
position 214. The two CP4 EPSPS protein
variants are structurally and functionally
equivalent
9 Dossier: Part II—Section 1.2.2.2
10 Dossier: Part II – Section 1.2.2.3 and additional information: 7/8/2017 and 11/3/2019
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3.4.2. Comparative analysis11
3.4.2.1. Overview of studies conducted for comparative analysis
Application EFSA-GMO-NL-2016-134 presents data on agronomic and phenotypic characteristics and
on forage and grain composition of the five-event stack maize (Table 5).
3.4.2.2. Experimental field trial design and statistical analysis
At each site, the following materials were grown: the five-event stack maize, the comparator maize
MPA640B and four commercial non-GM maize reference varieties (hereafter ‘non-GM reference
varieties’). All materials were treated with conventional herbicides management regimes; in addition,
the field trials included the five-event stack maize exposed to the intended glyphosate-containing
herbicide on top of the conventional herbicides.
The agronomic, phenotypic and compositional data were analysed as specified by EFSA GMO
Panel (EFSA GMO Panel, 2010a,b, 2011a). This includes, for each of the two treatments of the five-
event stack maize, the application of a difference test (between the GM stack maize and its non-GM
comparator) and an equivalence test (between the GM stack maize and the set of non-GM reference
varieties).12 The results of the equivalence test are categorised into four possible outcomes (I–IV,
ranging from equivalence to non-equivalence).13
3.4.2.3. Suitability of selected test materials
Selection of the GM maize line and comparator
To produce the five-event stack maize, the single events MON 87427, MON 87460, MON 89034,
MIR162 and NK603 were transferred in the genetic background of two different non-GM inbred lines,
LH244 and LH287.
In subsequent subsections, GM maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9
NK603 refers to hybrid (F1 generation) obtained crossing GM inbred line LH244 (carrying MIR162) with
GM inbred line LH287 (carrying MON 87427 9 MON 87460 9 MON 89034 9 NK603).
The comparator selected in the field trials is the hybrid maize MPA640B that was obtained by
crossing the non-GM inbred lines LH244 and LH287. As documented by the pedigree, the GMO
Panel considers the produced comparator acceptable for the comparative analysis.
The five-event stack maize and the non-GM comparator, both with a comparative relative maturity
(CRM) of 110, are appropriate for growing in a range of environments across North America.
Table 5: Overview of the comparative analysis studies to characterise the five-event stack maize
provided in application EFSA-GMO-NL-2016-134
Study focus Study details Comparator
Non-GM reference
varieties
Agronomic and phenotypic
analysis
Field study, USA, 2014, eight sites(a) MPA640B 17(b)
Compositional analysis Field study, USA, 2014, eight sites(c) 18(b)
GM: genetically modified.
(a): The field trials were located in Jefferson, IA; Vermilion, IL; Warren, IL; Shelby, IL; Pawnee, KS; Perquimans, NC; Miami, OH
and Berks, PA.
(b): Non-GM maize hybrids used in the 2014 field trials were Channel 211-97, Channel 213-88, Dekalb DKC62-06, Dekalb
DKC63-43, Gateway 6158, LG2540, LG2548, Midland Phillips, Mycogen 2H721, Mycogen 2J790, NC + 5220, NH6280,
NH6769, Phillips 717, Seed Consultants 1112, Stewart S588, Stewart S602 and Stine 9724. All the non-GM hybrids were
used for both the agronomic and phenotypic characterisation and the compositional analyses except the non-GM hybrid
maize Stewart S588 that was used for the compositional analysis only.
(c): The field sites were located in Jefferson, IA; Webster, IA; Champaign, IL; Warren, IL; Shelby, IL; Pawnee, KS; Miami, OH;
and Berks, PA.
11 Dossier: Part II – Section 1.3; additional information: 24/4/2017 and 7/8/2017.
12 The purpose of the test of equivalence is to evaluate the estimated mean values for maize
MON 87427 9 MON 89034 9 MIR162 9 NK603 taking into account natural variability as defined by a set of non-GM
reference varieties with a history of safe use for consumption as food or feed.
13 In detail, the four outcomes are: category I (indicating full equivalence to the non-GM reference varieties); category II
(equivalence is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and
category IV (indicating non-equivalence).
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Selection of non-GM reference varieties
The non-GM reference varieties (see Table 5) with a CRM ranging from 108 to 115 were selected
by the applicant and at each selected site four of them were tested. On the basis of the information
provided on CRM classes, the GMO Panel considers the selected non-GM reference varieties
appropriate for the comparative assessment.
Seed production and quality
The seeds of the five-event stack maize and the comparator used in the 2014 field trials (see
Table 5) were produced, harvested and stored under similar conditions. The seed lots were verified for
their identity via event specific PCR analysis. The mean germination rates of the five-event stack maize
and the comparator were 100% and 99%, respectively. The GMO Panel considers that the starting seed
used as test material in the agronomic, phenotypic and compositional studies was of suitable quality.
Conclusion on suitability
The GMO Panel is of the opinion that the five-event stack maize, the non-GM comparator and the
non-GM reference varieties were properly selected and are of adequate quality. Therefore, the test
materials are considered appropriate for the comparative analysis.
3.4.2.4. Representativeness of the receiving environments
Selection of field trial sites
The selected field trial sites were located in commercial maize-growing regions of North America.14
The soil characteristics of the selected fields were diverse,15 corresponding to optimal, near-optimal
and sub-optimal conditions for maize cultivation (Sys et al., 1993). The GMO Panel considers that the
selected sites reflect commercial maize-growing regions in which the test materials are likely to be
grown.
Meteorological conditions
Maximum and minimum mean temperatures and sum of precipitations were provided on a monthly
basis. No exceptional weather conditions were reported at any of the selected field trial sites. The
GMO Panel considers that the meteorological dataset falls within the range of climatic conditions
normally occurring at these sites.
Management practices
The field trials included plots containing five-event stack maize, plots with the comparator and plots
with non-GM reference varieties, all managed according to local agricultural practices. In addition, the
field trials included plots containing five-event stack maize managed following the same agricultural
practices, plus exposed to the intended glyphosate-containing herbicide. Glyphosate was applied at the
V2–V4 growth stage. Despite not considered a normal agricultural practice, thinning was applied at all
field trial sites to achieve a more homogeneous plant density across plots. The GMO Panel considers
that the management practices, including sowing, harvesting and application of plant protection
products, were acceptable for the field trials.
Conclusion on representativeness
The GMO Panel concludes that the geographical locations, soil characteristics, meteorological
conditions and most of the management practises are typical for receiving environments where the
test materials could be grown.
3.4.2.5. Agronomic and phenotypic endpoints
Thirteen agronomic and phenotypic endpoints,16 plus information on abiotic stressors, disease
incidence and arthropod damage, were collected from eight different sites (see Table 5).
14 For event MON 87460, a comparative analysis was specifically conducted under drought conditions (Table 2). Considering that
there is no indication of an interaction between the events (see Section 3.4.1.4), it was not necessary to request the inclusion
of field trials under drought conditions for the five-event stack maize.
15 Soil types of the field trials were silty clay loam, loam, silt loam and sandy loam; soil organic matter ranged from 1.6% to
5.4%.
16 Early stand count, days to 50% pollen shed, days to 50% silking, stay green rating, ear height, plant height, dropped ears,
stalk lodged plants, root lodged plants, final stand count, grain moisture, test weight, yield.
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The endpoint dropped ears was not subjected to a formal statistical analysis (Section 3.4.2.2)
because more than 90% of the values were 0.
The results of the statistical analysis were the following:
• For maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 (treated with
conventional herbicides), the test of difference identified statistically significant differences with
the comparator for six endpoints.17 All these endpoints fell under equivalence category I or II,
except for final stand count for which the test of equivalence was not applied (because the
variation between the non-GM reference varieties was estimated to be 0).18
• For maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 (treated with the
intended herbicides), the test of difference identified statistically significant differences with the
comparator for eight endpoints.19 All these endpoints fell under equivalence category I or II,
except for days to 50% silking which fell under equivalence category III and final stand count
for which the test of equivalence was not applied.20
The GMO Panel considered the changes observed for the five-event stack maize with respect to the
non-GM comparator in final stand count (~1 plant/plot increase) and days to 50% silking (~1.5 days
increase). Taking into account the magnitude of the differences and the results observed for the other
endpoints, the GMO Panel considered that these differences do not affect the use of the field trials for
the comparative analysis. Whether the differences can lead to an environmental adverse effect is
considered in Section 3.5.
3.4.2.6. Compositional analysis
Forage and grain harvested from the field trials in the US in 2014 (Table 5) were analysed for 78
different constituents (nine in forage and 69 in grain), including the key constituents recommended by
the OECD (2002). For 15 grain components,21 more than 50% of the observations were below the
limit of quantification.
The statistical analysis was applied to a total of 63 constituents (9 in forage22 and 54 in grain23); a
summary of the outcome of the test of difference and the test of equivalence is presented in Table 6:
• For maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 treated with the
intended herbicide were identified 39 endpoints with statistically significant differences with its
non-GM comparator. All the endpoints fell under equivalence category I and II.
• For maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 treated with the
conventional herbicide, statistically significant differences with its non-GM comparator were
identified for 46 endpoints. All the endpoints fell under equivalence category I and II. Moisture
levels in forage fell under equivalence category III, although no statistically significant
differences were identified with the non-GM comparator.
17 Ear height, days to 50% pollen shed, plant height, days to 50% silking, final stand count and stalk lodged plants.
18 Estimated mean values for final stand count were 67.9 (non-treated GM maize), 67.7 (treated GM maize), 66.8 (non-GM
comparator) and 67.6 (non-GM reference varieties).
19 Early stand count, grain moisture, days to 50% pollen shed, plant height, root lodged plants, days to 50% silking, final stand
count, stalk lodged plants and yield.
20 Estimated mean values for final stand count were 67.9 (non-treated GM maize), 67.7 (treated GM maize), 66.8 (non-GM
comparator) and 67.6 (non-GM reference varieties). Estimated mean values for days to 50% silking were 66.0 (treated GM
maize), 64.7 (non-GM comparator) and 63.7 (non-GM reference varieties); equivalence limits: (61.7, 65.8).
21 Sodium, furfural and the fatty acids caprylic (C8:0), capric (C10:0), lauric (C12:0), myristic (C14:0), myristoleic (C14:1),
pentadecanoic (C15:0), pentadecenoic (C15:1), heptadecanoic (C17:0), heptadecenoic (C17:1), c-linolenic (C18:3),
eicosadienoic (C20:2), eicosatrienoic (C20:3) and arachidonic (C20:4).
22 Protein, moisture, neutral detergent fibre (NDF), acid detergent fibre (ADF), total fat, ash, calcium, phosphorus, and
carbohydrates by calculation.
23 Proximates (moisture, protein, total fat, ash, carbohydrates by calculation), fibre fractions (acid detergent fibre (ADF), neutral
detergent fibre (NDF), total detergent fibre (TDF)), amino acids (alanine, arginine, aspartic acid, cystine, glutamic acid,
glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine,
valine), fatty acids (palmitic acid (C16:0), palmitoleic acid (C16:1), stearic acid (C18:0), oleic acid (C18:1), linoleic acid
(C18:2), linolenic acid (C18:3), arachidic acid (C20:0), eicosenoic acid (C20:1), behenic acid (C22:0)) , vitamins (vitamin A (b-
carotene), vitamin B1 (thiamine) , vitamin B2 , vitamin B6 , vitamin E (a-tocopherol), niacin and folic acid) , minerals (calcium,
copper, iron, magnesium, manganese, phosphorus, potassium and zinc) and other compounds (phytic acid, raffinose, ferulic
acid and p-coumaric acid).
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The GMO Panel assessed all the compositional differences between maize MON 87427 9 MON
87460 9 MON 89034 9 MIR162 9 NK603 and its non-GM comparator, taking into account the
potential impact on plant metabolism and the natural variability observed for the set of non-GM
reference varieties. No endpoints showing significant differences between the five-event stack maize
and the non-GM comparator and falling under category III/IV were identified.
3.4.2.7. Conclusion on the comparative assessment
Taking into account the natural variability observed for the set of non-GM reference varieties, the
GMO Panel concludes that:
• None of the differences identified in the agronomic and phenotypic characteristics tested
between the five-event stack maize and the non-GM comparator needs further assessment for
environmental safety, except for the changes in days to 50% silking and final stand count
which are considered in Section 3.4.4.1.
• None of the differences identified in forage and seed composition between the five-stack maize
and the non-GM comparator needs further assessment regarding food and feed safety.
3.4.3. Food and feed safety assessment
3.4.3.1. Effects of processing
Maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 will undergo existing
production processes used for conventional maize. No novel production process is envisaged. Based on
the outcome of the comparative assessment, processing of the five-event stack maize MON
87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 into food and feed products is not expected
to result in products being different from those of conventional non-GM maize varieties.
Table 6: Outcome of the comparative compositional analysis in seeds and forage for maize MON
87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603. The table shows the number of
endpoints in each category.
Test of difference(a)
Treated(c) Not-treated(c)
Not
different
Significantly
different
Not different
Significantly
different
Test of
equivalence(b)
Category I/II 21 39(d) 13 46(d)
Category III/IV – – 1(e) –
Not categorised 3(f) – 3(f) –
Total endpoints 63 63
(a): Comparison between for maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 and its non-GM comparator.
(b): Four different outcomes: category I (indicating full equivalence to the non-GM reference varieties); category II (equivalence
is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and category IV
(indicating non-equivalence). Not categorised means that the test of equivalence was not applied because of the lack of
variation among the non-GM reference varieties.
(c): Treated/not-treated with intended herbicide glyphosate.
(d): Endpoints with significant differences between maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 and its
non-GM comparator falling in equivalence category I-II (treated and not-treated). For grain, both treated and not treated:
carbohydrates by calculation, alanine, arginine, aspartic acid, glutamic acid, glycine, isoleucine, lysine, phenylalanine,proline,
serine, threonine, tryptophan, tyrosine, valine, palmitic acid (C16:0), palmitoleic acid (C16:1), stearic acid (C18:0), oleic acid
(C18:1), linoleic acid (C18:2), linolenic acid (C18:3), eicosenoic acid (C20:1), total fat, folic acid, niacin, vitamin B1, vitamin B6,
vitamin E, total dietary fibre (TDF), manganese, magnesium, potassium, zinc, ferulic acid, p-coumaric acid, and raffinose. Not
treated only: protein, cystine/cysteine, histidine, leucine, arachidic acid (C20:0), vitamin A, phytic acid; treated only:
phosphorus. For forage, both treated and not treated: protein and carbohydrates by calculation; only not treated: phosphorus
(e): Endpoints falling under equivalence category III/IV although no statistically significant differences were identified with
respect to the non-GM comparator: moisture in forage (not-treated).
(f): Endpoints not categorised for equivalence and without significant differences between the MON 87427 9 MON
87460 9 MON 89034 9 MIR162 9 NK603 and its non-GM comparator: neutral detergent fibre (NDF), acid detergent fibre
(ADF) and total fat in forage (treated and not treated).
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3.4.3.2. Influence of temperature and pH on newly expressed proteins
The effects of temperature and pH on the newly expressed proteins in this five-event stack maize
have been previously evaluated by the GMO Panel (Table 2). No new information has been provided in
the context of this application.
3.4.3.3. Toxicology
Testing of newly expressed proteins
Seven proteins (Cry1A.105, Cry2Ab2, Vip3Aa20, PMI, CSPB, NPTII, CP4 EPSPS and its variant CP4
EPSPS L214P) are newly expressed in maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9
NK603 (Section 3.4.1). The GMO Panel has previously assessed these proteins in the context of the
single events (Table 2), and no safety concerns were identified for humans and animals. The GMO
Panel is not aware of any new information that would change this conclusion.
The potential for a functional interaction between the proteins newly expressed in maize MON
87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 has been assessed with regard to human and
animal health. The insecticidal proteins Cry1A.105 and Cry2Ab2 are delta-endotoxins acting through
cellular receptors found in target insect species. It is reported that the gastrointestinal tract of mammals,
including humans, lacks receptors with high specific affinity to Cry proteins (Hammond et al., 2013; Koch
et al., 2015). The Vip3Aa20 protein is a protein secreted by B. thuringiensis during its vegetative phase
acting in target insects via a mechanism similar to that of Cry proteins (Chakroun et al., 2016; Bel et al.,
2017). The CSPB protein is an RNA chaperone associated with enhanced abiotic stress tolerance in
bacteria and plants, through its interaction with RNA secondary structures, limiting their misfolding and
allowing cells to maintain cellular functions under various stress conditions (Phadtare et al., 2002a,b;
Castiglioni et al., 2008). The NPTII protein inactivates by phosphorylation a range of antibiotics (Fraley
et al., 1983). The CP4 EPSPS and PMI proteins are enzymes that catalyse distinct biochemical reactions
and act on unrelated substrates in the plant with high substrate specificity.
On the basis of the known biological function of the individual newly expressed proteins (Table 4),
there is currently no expectation for possible interactions relevant to the food and feed safety of maize
MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603.
In vitro protein degradation studies on Cry1A.105, Cry2Ab2, Vip3Aa20, PMI, CSPB, NPTII, CP4
EPSPS and its variant CP4 EPSPS L214P proteins have been previously evaluated by the GMO
Panel (Table 2). No new information has been provided in the context of this application.
The GMO Panel concludes that there are no safety concerns to human and animal health related to
the newly expressed proteins Cry1A.105, Cry2Ab2, Vip3Aa20, PMI, CSPB, NPTII CP4 EPSPS and its
variant CP4 EPSPS L214P protein in maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162
9 NK603.
Testing of new constituents other than proteins
No new constituents other than newly expressed proteins have been identified in maize MON
87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603. Therefore, no further food and feed safety
assessment of components other than the newly expressed proteins is required.
Information on altered levels of food and feed constituents
The five-event stack maize did not show any compositional differences to the non-GM comparator
that would require further assessment (Section 3.4.2.6).
Testing of the whole genetically modified food and feed
Based on the outcome of the molecular characterisation assessment, comparative analysis and
toxicological assessment, no indication of findings relevant to food/feed safety related to the stability and
expression of the inserts or to interaction between the transformation events, and no modifications of
toxicological concern in the composition of the five-event stack maize have been identified (see
Sections 3.4.1., 3.4.2.3 and 3.4.3.2). Therefore, animal studies on food/feed derived from maize MON
87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 are not necessary (EFSA GMO Panel, 2011a).
In accordance to Regulation (EU) No 503/2013, the applicant provided a 90-day oral repeated-dose
toxicity study in rats on whole food and feed from each of the maize single-event MON 87427, MON
87460, MON 89034, MIR162 and NK603. The five studies had already been provided in the context of the
single-event applications and assessed by the GMO Panel; no adverse effects related to the administration
of the respective GM diets had been identified (Table 2). In the context of the assessment of maize MON
Assessment of maize MON 87427 3MON 87460 3 MON 89034 3 MIR162 3 NK603 and subcombinations
www.efsa.europa.eu/efsajournal 18 EFSA Journal 2019;17(8):5774
87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 and in order to fulfil the requirements of
Regulation (EU) No 503/2013, the applicant provided additional information upon EFSA’s request for the
studies on the single-event maize MON 87427, MON 87460, MON 89034, MIR162 and NK603.
The GMO Panel has previously assessed the above-mentioned additional information on MON 87427,
MON 89034, MIR162 and NK603 in the context of another application under Regulation (EU) 503/2013
(EFSA GMO Panel, 2019). The additional histopathology24 provided for the 90-day study on maize MON
87460 showed sporadic histopathological findings compatible with the spontaneous background
pathology of rats of this strain and age.
The GMO Panel concludes that these studies are in line with the legal requirements and confirms
that there are no indications of adverse effects related to the 90-day administration to rats of diets
including grains from maize MON 87427, MON 89034, MON 87460, NK603 and MIR162.
The GMO Panel noted that the incorporation rate of maize selected in these studies is up to 41.5%,
in line with commercially available rodent diets. It has been recently reported that a diet incorporating
50% maize may be tolerated without inducing nutritional imbalances in rats after 90-day
administration (Steinberg et al., 2019), but the GMO Panel considers that further scientific confirmation
is needed before this 50% maize incorporation rate is applicable in future studies.
3.4.3.4. Allergenicity
For the allergenicity assessment, a weight-of-evidence approach was followed, taking into account all
the information obtained on the newly expressed proteins, as no single piece of information or
experimental method yields sufficient evidence to predict allergenicity (Codex Alimentarius, 2009; EFSA
GMO Panel, 2011a; Regulation 503/2013). In addition, when known functional aspects of the newly
expressed protein or structural similarity to known adjuvants may indicate an adjuvant activity, the
possible role of these proteins as adjuvants is considered. When newly expressed proteins with a potential
adjuvant activity are expressed together, possible interactions increasing adjuvanticity and impacting the
allergenicity of the GM crop are assessed. In addition, an assessment of specific newly expressed proteins
in relation to their potential to cause celiac disease was also performed (EFSA GMO Panel, 2017a).
Assessment of allergenicity of newly expressed proteins
For allergenicity, the GMO Panel has previously evaluated the safety of the proteins Cry1A.105,
Cry2Ab2, Vip3Aa20, PMI, CSPB, NPTII and CP4 EPSPS (including its variant CP4 EPSPS L214P) proteins
individually, and no concerns on allergenicity were identified in the context of the applications assessed
(Table 2). No new information on allergenicity of these proteins that might change the previous
conclusions of the GMO Panel in the context of the GM events assessed has become available.25 Based
on the current knowledge, and as none of the newly expressed proteins showed allergenicity, no
reasons for concerns regarding the simultaneous presence of these newly expressed proteins in this
five-event stack maize affecting their allergenicity are expected.
For adjuvanticity, the Bt protein Cry1Ac has been suggested to possess adjuvant activity based on
animal studies on Cry1Ac when applied at relatively high doses (e.g. Vazquez et al., 1999). The GMO
Panel has previously evaluated the safety of the Cry1A.105, Cry2Ab2 and Vip3Aa20 proteins and no
concerns on adjuvanticity in the context of the applications assessed were identified (Table 2). The
levels of Bt proteins in this five-event stack maize are comparable to those in the respective single
maize events (Section 3.4.1.4). From the limited experimental evidence available, the GMO Panel did
not find indications that the presence of the Bt proteins at the levels expressed in this five-event stack
maize might act as adjuvants with the potential to enhance a specific immunoglobulin E (IgE) response
and to favour the development of an allergic reaction.
The applicant provided spontaneous information on the safety of the Cry1A.105, Cry2Ab2, CSPB, NPTII
and CP4 EPSPS proteins regarding their potential hazard to cause a celiac disease response. For such
assessment, the applicant followed the principles described in the EFSA GMO Panel guidance document
(2017). Briefly, bioinformatics searches for sequence identity with proteins eliciting celiac disease revealed
partial matches with and without the Q/E-X1-P-X2 motif for the Cry1A.105 protein requiring further
24 Aorta, bone (sternum) with bone marrow, cecum, cervix (females only), eyes with optic nerves, lung (including bronchi),
mandibular lymph node, Peyer’s Patches, skin with mammary gland (females only), skin from males (similar area), esophagus,
pituitary, prostate (males only), mandibular salivary gland, seminal vesicles (males only), skeletal muscle, trachea, urinary
bladder, uterus (females only), and vagina (females only) from all animals given the control and 33% test diet.
25 Information on the safety of the Cry1A.105, Cry2Ab2, CspB, NptII and CP4 EPSPS proteins regarding their potential hazard to
cause a celiac disease response has been spontaneously submitted by the applicant despite requirements laid down in the
recent EFSA guidance on allergenicity (2017) are not applicable to this dossier, as described in Section ‘1.5 Transition period’.
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investigation. Based on additional considerations on position and nature of amino acids flanking the QLPQ
motif, such as the absence of prolines at specific positions and the charge and size of adjacent amino acids
(EFSA GMO Panel, 2017a), the sequences containing the motif do not raise concern as they fail to mimic
gluten sequences. Two additional partial sequence matches lacking the motif were also identified and
subjected to a HLA-DQ-peptide structure modelling using a publicly available crystal structure of HLA-DQ2-
T-cell receptor interactions as a reference.26,27 These two sequences were associated to a potential
gamma-gliadin-derived peptide, for which the 9-amino acid core sequence has not been determined and
which lacks a proven clinical relevance28 (Tye-Din et al., 2010). For this reason, these two sequences are
not considered relevant. Therefore, no indications of safety concerns were identified by the GMO Panel.
Finally, it is acknowledged that the platform used by the applicant for the modelling is in line with the
recommendations by EFSA (EFSA GMO Panel, 2017b). However, in general, it will be also necessary to
perform direct comparisons between the sequence(s) under question and the matching clinically relevant
celiac diseaseT-cell epitope(s) included in the pertinent HLA-DQ crystal structure.
Assessment of allergenicity of the GM plant products
The GMO Panel regularly reviews the available publications on food allergy to maize. However,
maize is not considered a common allergenic food29 (OECD, 2002). Therefore, the GMO Panel does not
request experimental data to analyse the allergen repertoire of GM maize.
In the context of this application and considering the data from the molecular characterisation, the
compositional analysis and the assessment of the newly expressed proteins (Sections 3.4.1, 3.4.2 and
3.4.3), the GMO Panel identified no indications of a potentially increased allergenicity of food and feed
derived from this five-event stack maize with respect to that derived from the non-GM comparator.
3.4.3.5. Dietary exposure assessment to new constituents
In line with Regulation (EU) No 503/2013 the applicant provided dietary exposure estimates to CP4
EPSPS, CSPB, NPTII, Cry1A.105, Cry2Ab2, Vip3Aa20, and PMI proteins newly expressed in MON
87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 maize. Dietary exposure was estimated
based on protein expression levels reported in this application for the five-event stack maize treated
with the intended herbicide, the current available consumption data and feed practices, the foods and
feeds currently available on the market and the described processing conditions.
Table 7 describes the protein expression levels used to estimate both human and animal dietary exposure.
Table 7: Mean values (n = 20, lg/g dry weight and lg/g fresh weight) for newly expressed proteins
in grains and forage from MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603
maize treated with the intended herbicide(a)
Protein
Tissue/developmental stage
Grains/R6
(lg/g dry weight and lg/g fresh weight)
Forage/R5 (lg/g dry weight)
CP4 EPSPS(b) 15.0/13 210
CSPB 0.082/0.074 0.079
NPTII 0.0063/0.0057(c) 0.18
Cry1A.105 8.1/7.3 26
Cry2Ab2 1.6/1.5 34
Vip3Aa20 38/33(d) 69
PMI 1.2/1.1(d) 4
EPSPS: 5-enolpyruvylshikimate-3-phosphate synthase; CSPB: cold shock protein B; NPTII: neomycin phosphotransferase II
protein; PMI: phosphomannose isomerase; LOQ: limit of quantification.
(a): Intended herbicide: glyphosate.
(b): CP4 EPSPS levels in MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 maize are the sum of two protein
variants, CP4 EPSPS (expressed in MON 87427 and NK603) and CP4 EPSPS L214P (expressed in NK603).
(c): N = 6 since fourteen samples were reported as below the LOQ (LOQ = 0.005 lg/g fw).
(d): Fresh weight values for Vip3Aa20 and PMI proteins used to estimate human dietary exposure were calculated by multiplying the
dry weight values by a dry weight correction factor of 0.88 to account for approximately 12% moisture content in the grains.
26 https://www.rcsb.org/
27 https://www.rosettacommons.org/software
28 This aspect points out the importance of developing comprehensive database regarding celiac disease epitopes that is
appropriately built, curated regularly and designed for risk assessment purposes.
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Human dietary exposure29
Dietary exposure was estimated across different European countries on different population groups:
young population (infants, toddlers, ‘other children’), adult population (adolescents, adults, elderly and
very elderly) and special populations (pregnant and lactating women).
For the purpose of estimating dietary exposure, the levels of newly expressed proteins in MON
87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 maize grains were derived from replicated
field trials (four replicates from five locations) in the 2014 US growing season. Mean values (fresh
weight) are considered as the most adequate to estimate dietary exposure (see Table 7). Since no
specific consumption data were available on commodities containing, consisting of or obtained from
MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 maize grains, a conservative scenario
with 100% replacement of conventional maize by the GM maize was considered. Consumption figures
for all relevant commodities (e.g. corn flakes, sweet corn, popcorn, etc.) were retrieved from the EFSA
Comprehensive European Food Consumption Database (EFSA consumption database).30 Maize oil was
excluded from the assessment since no proteins are expected to be present in the oil.
For the acute dietary exposure estimations, the applicant assigned to the processed commodities
the mean value reported for the newly expressed proteins in maize grains. This is a conservative
approach as neither recipes nor the effect of processing is considered on the final concentration of
newly expressed proteins. Summary statistics from the EFSA consumption database were used.31
Acute dietary exposure in high consumers within each dietary survey and age class was estimated by
summing the exposure derived from the 95th percentile consumption for the dominant food
commodity32 among consumers only and those exposures derived from the mean consumption of the
remaining food categories in the total population (EFSA, 2015). Table 8 shows the highest acute
dietary exposure for the different newly expressed proteins; dietary exposure estimates ranged
between 0.02 lg/kg body weight (bw) per day for NPTII in adults (18–65 years) and 268 lg/kg bw
per day for Vip3Aa20 in toddlers (1–3 years). The most relevant food commodities in terms of
contribution to the exposure were sweet corn (toddlers) and popcorn (adults).
The GMO Panel estimated chronic dietary exposure to CP4 EPSPS, CSPB, NPTII, Cry1A.105, Cry2Ab2,
Vip3Aa20 and PMI proteins. Individual consumption data of the relevant food commodities were
retrieved from the EFSA Consumption Database, using dietary surveys with at least two days
consumption and covering a total of 22 European countries.33 Different recipes and factors were
considered to estimate the amount of maize in the consumed commodities before assigning CP4 EPSPS,
CSPB, NPTII, Cry1A.105, Cry2Ab2, Vip3Aa20 and PMI proteins levels to the relevant commodities.34 No
losses in the newly expressed proteins during processing were considered, except for certain
commodities excluded from the exposure estimations (maize oil, corn starch, corn syrup). The 95th
Table 8: Highest acute dietary exposure to CP4 EPSPS, CSPB, NPTII, Cry1A.105, Cry2Ab2,
Vip3Aa20, and PMI proteins (lg/kg bw per day) estimated across European dietary
surveys and different age classes.
Acute dietary exposure (lg/kg bw per day)
CP4 EPSPS(a) CSPB NPTII Cry1A.105 Cry2Ab2 Vip3Aa20 PMI
Toddlers 106 0.6 0.05 59 12 268 8.9
Adults 46 0.3 0.02 26 5.3 117 3.9
bw: body weight; EPSPS: 5-enolpyruvylshikimate-3-phosphate synthase; CSPB: cold shock protein B; NPTII: neomycin
phosphotransferase II protein; PMI: phosphomannose isomerase.
(a): CP4 EPSPS levels in MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 maize are the sum of two protein
variants, CP4 EPSPS (expressed in MON 87427 and NK603) and CP4 EPSPS L214P (expressed in NK603).
29 Dossier: Part II – Section 2.4.
30 http://www.efsa.europa.eu/en/data/food-consumption-data
31 Summary statistics from the EFSA Comprehensive European Food Consumption Database accessed in September 2016.
32 Dominant food commodity refers to the food that will lead to the highest exposure among all consumed foods.
33 Austria, Belgium, Bulgaria, Cyprus, the Czech Republic, Germany, Denmark, Estonia, Finland, France, the United Kingdom,
Greece, Croatia, Hungary, Ireland, Italy, Latvia, the Netherlands, Portugal, Spain, Romania and Sweden.
34 Example: 100 g of maize bread are made with approximately 74 g of maize flour, and a reverse yield factor of 1.22 from the
conversion of maize grains into flour is used. This results in 29.7 µg of Vip3Aa20 per gram of maize bread as compared to
33 µg/g in the maize grains.
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percentile chronic exposure (highly exposed population) was derived from the distribution of the
individual dietary exposure estimates within each dietary survey and age class.
Table 9 shows the chronic dietary exposure to each of the newly expressed proteins across
European dietary surveys; dietary exposure ranged between 0.00005 lg/kg bw per day for NPTII
protein in elderly and very elderly population (> 65 years) and 148.4 lg/kg bw per day for Vip3Aa20
protein in infants (< 1 year). Main average contributors to the exposure in the dietary surveys with the
highest estimates were sweet corn in infants, and cornflakes in toddlers and ‘Other children’.
Animal dietary exposure35
Animal dietary exposure to CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, CSPB, NPTII and PMI
proteins was estimated following the consumption of maize grain, gluten feed, gluten meal and maize
forage/silage since these are the maize products entering the feed chain. A conservative scenario with
100% replacement of conventional maize products by the GM products was considered.
Mean levels of CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, CSPB, NPTII and PMI proteins in maize
grains and forage/silage were derived from field trials conduct in the 2014 US growing season (see
Table 7). To estimate the mean newly expressed proteins levels in maize gluten feed and gluten meal,
a factor of 2.6 and 7.1 folds respectively was applied, based on the protein content of gluten feed and
gluten meal relative to maize grain (OECD, 2002), assuming that no losses of newly expressed proteins
occur during processing.
Dietary exposure to CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, PMI, CSPB and NPTII proteins in
maize MON 87427 9 MON 87460 x MON 89034 9 MIR162 9 NK603 following the consumption of
maize grain, gluten feed and gluten meal was provided by the applicant across different animal species
(i.e. broiler, finishing pig and lactating dairy cattle), based on estimates for animal body weight, daily
feed intake and inclusion rates (percentage) of maize grain, gluten feed and gluten meal in animal
diets (OECD, 2009). Estimated dietary exposure was as follows:
– to CP4 EPSPS protein, 1,768 lg/kg bw per day in broiler chickens, 1,442 lg/kg bw per day in
dairy cattle and 869 lg/kg bw per day in finishing pig.
– to Cry1A.105 protein, 955 lg/kg bw per day in broiler chickens, 779 lg/kg bw per day in
dairy cattle and 469 lg/kg bw per day in finishing pig.
– to Cry2Ab2 protein, 189 lg/kg bw per day in broiler chickens, 154 lg/kg bw per day in dairy
cattle and 93 lg/kg bw per day in finishing pig.
– to Vip3Aa20 protein, 4,480 lg/kg bw per day in broiler chickens, 3,654 lg/kg bw per day in
dairy cattle and 2,200 lg/kg bw per day in finishing pig.
Table 9: Range of chronic dietary exposure estimates (95th percentiles, highly exposed population)
to CP4 EPSPS, CSPB, NPTII, Cry1A.105, Cry2Ab2, Vip3Aa20 and PMI proteins (lg/kg bw
per day) across European dietary surveys and different age classes
N
Chronic dietary exposure (lg/kg bw per day)
CP4
EPSPS(a)
CSPB NPTII Cry1A.105 Cry2Ab2 Vip3Aa20 PMI
Infants 11 0–58.4 0–0.3 0–0.03 0–32.8 0–6.7 0–148.4 0–4.9
Toddlers 14 3.2–54.4 0.02–0.3 0.001–0.02 1.8–30.5 0.4–6.3 8.1–138.0 0.3–4.6
Other children 19 8.6–47.6 0.05–0.3 0.004–0.02 4.8–26.8 1.0–5.5 21.8–120.9 0.7–4.0
Adolescents 18 1.9–35.7 0.01–0.2 0.001–0.002 1.0–20.0 0.2–4.1 4.7–90.6 0.2–3.0
Adults 19 0.9–17.9 0.005–0.1 0.0004–0.01 0.5–10.1 0.1–2.1 2.2–45.5 0.1–1.5
Elderly and very
elderly
18 0.1–11.0 0.001–0.1 0.00005–0.005 0.1–6.2 0.01–1.3 0.3–28.0 0.01–0.9
Special population(b) 4 5.3–26.0 0.03–0.1 0.002–0.01 3.0–14.6 0.6–3.0 13.4–66.0 0.4–2.2
bw: body weight; n: number of dietary surveys; EPSPS: 5-enolpyruvylshikimate-3-phosphate synthase; CSPB: cold shock protein
B; NPTII: neomycin phosphotransferase II protein; PMI: phosphomannose isomerase.
(a): CP4 EPSPS levels in MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 maize are the sum of two protein
variants, CP4 EPSPS (expressed in MON 87427 and NK603) and CP4 EPSPS L214P (expressed in NK603).
(b): Pregnant women and lactating women.
35 Dossier: Part II – Section 2.3.
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– to PMI protein, 141 lg/kg bw per day in broiler chickens, 115 lg/kg bw per day in dairy
cattle and 69 lg/kg bw per day in finishing pig.
– to CSPB protein, 9.7 lg/kg bw per day in broiler chickens, 7.9 lg/kg bw per day in dairy
cattle and 4.7 lg/kg bw per day in finishing pig.
– to NPTII protein, 0.7 lg/kg bw per day in broiler chickens, 0.6 lg/kg bw per day in dairy
cattle and 0.4 lg/kg bw per day in finishing pig.
The GMO Panel estimated dietary exposure to CP4 EPSPS, Cry1A.105, Cry2Ab2, Vip3Aa20, CSPB,
NPTII and PMI proteins in maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603
across different livestock animal species (beef and dairy cows, lamb and breeding swine) following the
consumption of maize forage/silage, based on estimates for animal body weight, daily feed intake and
inclusion rates of maize forage/silage in animal diets (OECD, 2009).
Estimated dietary exposure was as follows:
– to CP4 EPSPS protein, 4,032 lg/kg bw per day in beef, 4,846 lg/kg bw per day in dairy cow,
2,677 lg/kg bw per day in lamb, 969 lg/kg bw per day in breeding swine and 1,436 lg/kg
bw per day in layer hen.
– to Cry1A.105 protein, 500 lg/kg bw per day in beef, 600 lg/kg bw per day in dairy cow,
331 lg/kg bw per day in lamb, 120 lg/kg bw per day in breeding swine and 178 lg/kg bw
per day in layer hen.
– to Cry2Ab2 protein, 653 lg/kg bw per day in beef, 785 lg/kg bw per day in dairy cow,
433 lg/kg bw per day in lamb, 157 lg/kg bw per day in breeding swine and 233 lg/kg bw
per day in layer hen.
– to Vip3Aa20 protein, 1,324 lg/kg bw per day in beef, 1,592 lg/kg bw per day in dairy cow,
880 lg/kg bw per day in lamb, 318 lg/kg bw per day in breeding swine and 472 lg/kg bw
per day in layer hen.
– to PMI protein, 77 lg/kg bw per day in beef, 92 lg/kg bw per day in dairy cow, 51 lg/kg bw
per day in lamb, 18 lg/kg bw per day in breeding swine and 27 lg/kg bw per day in layer hen.
– to CSPB protein, 1.5 lg/kg bw per day in beef, 1.8 lg/kg bw per day in dairy cow, 1 lg/kg
bw per day in lamb, 0.3 lg/kg bw per day in breeding swine and 0.5 lg/kg bw per day in
layer hen.
– to NPTII protein, 3.4 lg/kg bw per day in beef, 4.1 lg/kg bw per day in dairy cow, 2.3 lg/kg
bw per day in lamb, 0.8 lg/kg bw per day in breeding swine and 1.2 lg/kg bw per day in
layer hen.
3.4.3.6. Nutritional assessment of endogenous constituents
The intended traits of the five-event stack maize MON 87427 9 MON 87460 9 MON
89034 9 MIR162 9 NK603 are herbicide- and drought tolerance and insect resistance, with no
intention to alter nutritional parameters. Comparison of the composition of maize MON 87427 9 MON
87460 9 MON 89034 9 MIR162 9 NK603 with the non-GM comparator and non-GM reference
varieties did not identify differences that would require further safety assessment. From these data,
the GMO Panel concludes that the nutritional impact of maize MON 87427 9 MON 87460 9 MON
89034 9 MIR162 9 NK603-derived food and feed is the same as that expected from the non-GM
comparator and non-GM reference varieties.
3.4.3.7. Conclusion of the food and feed safety assessment
The proteins CP4 EPSPS, CSPB, NPTII, Cry1A.105, Cry2Ab2, Vip3Aa20 and PMI newly expressed in
the five-event stack maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 do not raise
safety concerns for human and animal health. Interactions between these newly expressed proteins
raising food and feed safety concerns (toxicological, allergenicity and adjuvanticity) are not expected.
The nutritional impact of the five-event stack maize foods and feeds is expected to be the same as
those from the comparator and non-GM reference varieties. The GMO Panel concludes that the
five-event stack maize, as described in this application, is as safe as and nutritionally equivalent to the
non-GM comparator and the non-GM reference varieties tested.
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3.4.4. Environmental risk assessment36
Considering the scope of application EFSA-GMO-NL-2016-134, which excludes cultivation, the
environmental risk assessment (ERA) of maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9
NK603 mainly takes into account: (1) the exposure of microorganisms to recombinant DNA in the
gastrointestinal tract of animals fed GM material and of microorganisms present in environments
exposed to faecal material of these animals (manure and faeces); and (2) the accidental release into
the environment of viable maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 grains
during transportation and/or processing (EFSA GMO Panel, 2010b).
3.4.4.1. Persistence and invasiveness of the GM plant
Maize is highly domesticated, not winter hardy in colder regions of Europe, and generally unable to
survive in the environment without appropriate management. Occasional feral GM maize plants may
occur outside cultivation areas in the EU (e.g. Pascher, 2016), but survival is limited mainly by a
combination of low competitiveness, absence of a dormancy phase and susceptibility to plant
pathogens, herbivores and cold climate conditions (OECD, 2003). Field observations indicate that
maize grains may survive and overwinter in some EU regions, resulting in volunteers in subsequent
crops (e.g. Gruber et al., 2008; Palaudelmas et al., 2009; Pascher, 2016). However, maize volunteers
have been shown to grow weakly and flower asynchronously with the maize crop (Palaudelmas et al.,
2009). Thus, the establishment and survival of feral and volunteer maize in the EU is currently limited
and transient.
It is unlikely that the intended traits of maize MON 87427 9 MON 87460 9 MON 89034 9
MIR162 9 NK603 and the observed differences in days to 50% silking and final stand count (see
Section 3.4.2.5) will provide a selective advantage to maize plants, except when they are exposed to
glyphosate-containing herbicides, under drought-stress or infested by insect pests that are susceptible
to the Cry1A.105, Cry2Ab2 and/or Vip3Aa20 proteins.
The GMO Panel considers that the fitness advantage provided by the intended traits, and the
observed differences in days to 50% silking and final stand count (see Section 3.4.2.5) will not allow
the GM plant to overcome other biological and abiotic factors (described above) limiting plant’s
persistence and invasiveness. Therefore, the presence of the intended traits and other observed
differences will not affect the persistence and invasiveness of the GM plant.
In conclusion, the GMO Panel considers it very unlikely that maize MON 87427 9 MON 87460 9
MON 89034 9 MIR162 9 NK603 will differ from conventional maize hybrid varieties in its ability to
survive until subsequent seasons, or to establish occasional feral plants under European environmental
conditions in case of accidental release into the environment of viable maize
MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 grains.
3.4.4.2. Potential for gene transfer
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic
material, either through HGT of DNA, or through vertical gene flow via cross-pollination from feral
plants originating from spilled grains.
Plant-to-microorganism gene transfer
The probability and potential adverse effects of HGT of the recombinant DNA have been assessed
in previous GMO Panel Scientific Opinions for the single events (see Table 2). This assessment included
consideration of homology-based recombination processes, as well as non-homologous end joining and
microhomology-mediated end joining. Possible fitness advantages that the bacteria in the receiving
environments would gain from acquiring recombinant DNA were considered. No concern as a result of
an unlikely, but theoretically possible, HGT of the recombinant genes to bacteria in the gut of
domesticated animals and humans fed GM material or other receiving environments was identified.
The applicant submitted updated bioinformatic analysis for each of the single events in order to assess
the possibility for HGT by HR.
The updated bioinformatic analyses provided in this application for the events MON 87427,
MON 89034, MIR162 and NK603 have recently been assessed by the GMO Panel in the context of
other applications (EFSA GMO Panel, 2019). The GMO Panel concluded that the unlikely, but
36 Dossier: Part II – Section 5.
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theoretically possible, horizontal transfer of recombinant genes from these maize events to bacteria did
not raise any environmental safety concern.
For the event MON 87460, the probability and potential adverse effects of HGT of the recombinant
DNA was assessed by the GMO Panel in 2012 (EFSA GMO Panel, 2012a). Three scenarios for HGT
were analysed: (1) the mobilisation of nptII by the cre/lox system, (2) transfer of nptII by double HR
to a Ti-plasmid of A. tumefaciens, and (3) substitutive HR of nptII or cspB genes to the bacteria
harbouring natural variants of such genes. The GMO Panel considered that the stabilisation of the
loxP-nptII-loxP fragment due to the Cre recombination system present in bacteria containing a P1 or
P1-like bacteriophage was unlikely.
Updated bioinformatic analysis for MON 87460 did not result in new information which would
change previous conclusions on possible HGT as described in the three scenarios above. There is
sufficient sequence identity and length of the nptII gene with bacterial DNA for HR but not for the
codon-optimised cspB gene from B. subtilis. Other genetic elements with sequence identity to bacterial
DNA are the T-tr7 intervening sequence upstream of the nptII, and the left border of the Ti cassette
downstream of the nptII which were already considered for facilitating HGT. Double HR between these
sequences and the corresponding sequences in the A. tumefaciens Ti-plasmid would result in the
insertion of the nptII expression cassette (P35S/nptII/T-nos) and the concomitant loss of a naturally
occurring Ti-plasmid sequence resulting in a Ti-plasmid that would not promote for plant tumour
formation (EFSA GMO Panel, 2012a). Due to the selective disadvantage of such bacterial recipients for
growing in plants, and the natural abundance of nptII genes in the environmental bacterial
communities, the GMO Panel concludes that there was no indication for a risk to human or animal
health or to the environment.
Synergistic effects of the recombinant genes, for instance due to combinations of recombinogenic
sequences, which would cause an increase in the likelihood for HGT or a selective advantage were not
identified.
Therefore, the GMO Panel concludes that the unlikely, but theoretically possible, horizontal transfer
of recombinant genes from this five-event stack maize to bacteria does not raise any environmental
safety concern.
Plant-to-plant gene transfer
The potential for occasional feral maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9
NK603 plants originating from grain import spills to transfer recombinant DNA to sexually compatible
plants and the environmental consequences of this transfer were considered.
For plant-to-plant gene transfer to occur, imported GM maize grains need to germinate and develop
into plants in areas containing sympatric wild relatives and/or cultivated maize with synchronous
flowering and environmental conditions favouring cross-pollination.
Maize is an annual predominantly cross-pollinating crop. Cross-fertilisation occurs mainly by wind
(OECD, 2003). Vertical gene transfer from maize is limited to Zea species. Wild relatives of maize
outside cultivation are not known/reported in Europe (Eastham and Sweet, 2002; OECD, 2003; EFSA,
2016; Trtikova et al., 2017). Therefore, potential vertical gene transfer is restricted to maize and
weedy Zea species, such as teosintes, and/or maize-teosinte hybrids, occurring in cultivated areas
(EFSA, 2016, Trtikova et al., 2017).
The potential of spilled maize grains to establish, grow and produce pollen is extremely low and
transient (see Section 3.4.4.1). Therefore, the likelihood/frequency of cross-pollination between
occasional feral GM maize plants resulting from grain spillage, and weedy or cultivated Zea plants is
considered extremely low (EFSA, 2016). Even if cross-pollination would occur, the GMO Panel is of the
opinion that environmental effects as a consequence of the spread of genes from occasional feral GM
maize plants in Europe will not differ from that of conventional maize varieties.
3.4.4.3. Interactions of the GM plant with target organisms
Taking the scope of application EFSA-GMO-NL-2016-134 into account (no cultivation), potential
interactions of occasional feral maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603
plants arising from grain import spills with the target organisms are not considered a relevant issue.
3.4.4.4. Interactions of the GM plant with non-target organisms
Given that environmental exposure of non-target organisms to spilled GM grains or occasional feral
GM maize plants arising from spilled maize MON 87427 9 MON 87460 9 MON 89034 9
MIR162 9 NK603 grains is limited and because ingested proteins are degraded before entering the
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environment through faecal material of animals fed GM maize, potential interactions of maize
MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 with non-target organisms are not
considered by the GMO Panel to raise any relevant environmental safety concern. Interactions that
may occur between the Bt proteins will not alter this conclusion.
3.4.4.5. Interactions with abiotic environment and biogeochemical cycles
Given that environmental exposure to spilled grains or occasional feral maize MON 87427 9
MON 87460 9 MON 89034 9 MIR162 9 NK603 plants arising from grain import spills is limited, and
because ingested proteins are degraded before entering the environment through faecal material of
animals fed GM maize, potential interactions with the abiotic environment and biogeochemical cycles
are not considered by the GMO Panel to raise any environmental safety concern.
3.4.4.6. Conclusion of the environmental risk assessment
The GMO Panel concludes that it is unlikely that the maize MON 87427 9 MON 87460 9 MON 89034
9 MIR162 9 NK603 would differ from conventional maize varieties in its ability to persist under
European environmental conditions. Considering the scope of application EFSA-GMO-NL-2016-134,
interactions of occasional feral maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603
plants with the biotic and abiotic environment are not considered to be relevant issues. The analysis of
HGT from the five-event stack maize to bacteria does not indicate a safety concern. Therefore,
considering the combined traits and their interactions, the outcome of the comparative analysis, the
routes and levels of exposure, the GMO Panel concludes that maize MON 87427 9 MON 87460 9
MON 89034 9 MIR162 9 NK603 would not raise safety concerns in the event of accidental release of
viable GM maize grains into the environment.
3.4.5. Conclusion on the five-event stack maize MON 87427 3 MON
87460 3 MON 89034 3 MIR162 3 NK603
No new data on the five single maize events MON 87427, MON 87460, MON 89034, MIR162 and
NK603 that would lead to a modification of the original conclusions on their safety were identified.
The combination of maize events MON 87427, MON 87460, MON 89034, MIR162 and NK603 in the
five-event stack maize did not give rise to issues concerning the molecular, agronomic/phenotypic or
compositional characteristics of the five-event stack maize that would be of concern for food and feed
safety and nutrition.
The newly expressed proteins in the five-event stack maize do not raise safety concerns for human
and animal health and the environment in light of the scope of this application.
No indications of interactions between the events based on the biological functions of the newly
expressed proteins that would raise a safety issue were identified in maize MON 87427 9 MON
87460 9 MON 89034 9 MIR162 9 NK603. Comparison of the levels of the newly expressed proteins
between the five-event stack maize and those of the single maize events did not reveal an interaction
at protein expression level.
Considering the combined traits and their potential interactions, the outcome of the comparative
analysis, and the routes and levels of exposure, the GMO Panel concludes that maize
MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 would not raise safety concerns in the
event of accidental release of viable GM maize grains into the environment.
No scientific information that could change the conclusions on this five-event stack maize was
retrieved through systematic literature searches covering the 10 years before submission of the
application and the period since the time of validity of the application. The GMO Panel concludes that
maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603, as described in this application,
is nutritionally equivalent to and as safe as the comparator and the non-GM reference varieties tested.
3.5. Risk assessment of the subcombinations37
Subcombinations previously assessed in the frame of other applications are discussed in
Section 3.5.1. The strategy followed for the subcombinations that have not been previously assessed
(Section 3.5.2) has been described by the GMO Panel.38 In this case, the risk assessment takes as its
starting point the assessment of the single maize events, and uses the data generated for the five-
37 Additional information: 24/5/2018.
38 115th GMO Panel meeting (Annex 1 of the minutes: http://www.efsa.europa.eu/sites/default/files/event/170517-m.pdf).
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event stack as well as all the additional data available on subcombinations previously assessed by the
GMO Panel (Table 2).
3.5.1. Subcombinations previously assessed
The GMO Panel has previously assessed eleven subcombinations and no safety concerns were
identified: the two-event maize stack MON 89034 9 NK603; the three-event stack maize
MON 87427 9 MON 89034 9 NK603 and all its subcombinations; the four-event stack maize MON
87427 9 MON 89034 9 MIR162 9 NK603 and all its subcombinations (see Table 2). Literature
searches covering the 10 years before submission of the application (January 2006–October 2016) and
the period since the time of validity of the application revealed no new scientific information relevant
to the risk assessment of these maize stacks.39 Consequently, the GMO Panel considers that its
previous conclusions on these subcombinations remain valid.
3.5.2. Subcombinations not previously assessed
Out of 25 subcombinations included in the scope of this application, 14 have not been previously
assessed by the GMO Panel, and no experimental data were provided for these maize stacks (see
Table 10).
3.5.2.1. Stability of the events
The genetic stability of the inserted DNA over multiple generations in the five single maize events
was demonstrated previously (see Table 2). Integrity of the events was demonstrated in the five-event
stack maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 (Section 3.4.1.2) and the
previously assessed maize subcombinations (EFSA GMO Panel, 2009, 2017a, 2019). The GMO
Panel finds no reasons to expect the loss of integrity of the events in the maize subcombinations not
previously assessed (see Table 10).
3.5.2.2. Expression of the events
The GMO Panel assessed whether any combination of the five events by conventional crossing
could result in significant changes in expression levels of the newly expressed proteins, as this could
indicate an unexpected interaction between the events. Based on current knowledge of the molecular
elements introduced, there is no reason to expect interactions that would affect the levels of the newly
expressed proteins in the 14 subcombinations compared with those in the single maize events. This
assumption was confirmed by comparing the levels of the newly expressed proteins of each single
maize event with those of the five-event stack maize. The levels were similar in the five-event stack
Table 10: Maize stacks not previously assessed and covered by the scope of application EFSA-GMO-
NL-2016-134
Degree of stacking Events
Four-event stack MON 89034 9 MON 87460 9 MIR162 9 MON 87427
NK603 9 MON 87460 9 MIR162 9 MON 87427
NK603 9 MON 89034 9 MON 87460 9 MON 87427
NK603 9 MON 89034 9 MON 87460 9 MIR162
Three-event stack MON 87460 9 MIR162 9 MON 87427
MON 89034 9 MON 87460 9 MON 87427
MON 89034 9 MON 87460 9 MIR162
NK603 9 MON 87460 9 MON 87427
NK603 9 MON 87460 9 MIR162
NK603 9 MON 89034 9 MON 87460
Two-event stack MON 87460 9 MON 87427
MON 87460 9 MIR162
MON 89034 9 MON 87460
NK603 9 MON 87460
39 Dossier: Part II – Section 7; additional information: 13/8/2018; 15/11/2018.
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maize and in the single events except for CP4 EPSPS, which showed, in general, the expected higher
level in the stack resulting from the combination of the single events MON 87427 and NK603
(Section 3.4.1.3 and Appendix A). Therefore, there was no indication of an interaction at protein
expression level. In addition, expression data from the two-event stack maize MON 89034 9 NK603
(EFSA GMO Panel, 2009), the three-event stack MON 87427 9 MON 89034 9 NK603 (EFSA GMO
Panel, 2017a) and the four-event stack MON 87427 9 MON 89034 9 MIR162 9 NK603 (EFSA GMO
Panel, 2019) were similar to those observed in each of the single maize events or showed in general
the expected higher levels for CP4 EPSPS. This supports the conclusion that interactions affecting the
expression levels of the newly expressed proteins are not expected in the 14 subcombinations not
previously assessed and included in the scope of application EFSA-GMO-NL-2016-134.
3.5.2.3. Potential functional interactions between the events
The GMO Panel assessed the potential for interactions between maize events in the 14
subcombinations not previously assessed (Table 10), taking into consideration intended traits and
unintended effects.
Based on the known biological functions of the individual newly expressed proteins (Table 4), there
is currently no expectation for possible interactions relevant for the food and feed or environmental
safety between these proteins in those subcombinations. The GMO Panel took into account all the
intended and potential unintended effects considered in the assessment of the five single events, the
previously assessed subcombinations (Table 2) and the five-event stack maize. It is concluded that
none of these events would raise safety concerns when combined in any of these maize
subcombinations. The GMO Panel considers that no further data are needed to complete the
assessment of subcombinations from the five-event stack maize.
3.5.3. Conclusion
Since no new safety concerns were identified for the previously assessed subcombinations, the
GMO Panel considers that its previous conclusions on these maize subcombinations remain valid. For
the remaining 14 subcombinations included in the scope of application EFSA-GMO-NL-2016-134, no
experimental data have been provided. For these subcombinations, the GMO Panel assessed the
possibility of interactions between the events and concluded that these combinations would not raise
safety concerns. These subcombinations are therefore expected to be as safe as and nutritionally
equivalent to the single maize events, the previously assessed subcombinations and the five-event
stack maize.
3.6. Post-market monitoring40
3.6.1. Post-market monitoring of GM food/feed
The GMO Panel concluded that the five-event stack maize, as described in this application, is
nutritionally equivalent to and as safe as the non-GM comparator and the non-GM reference varieties
tested (Section 3.4.3.7). Eleven of the subcombinations have been previously assessed and no safety
concerns were identified. The 14 subcombinations not previously assessed and included in the scope of
application EFSA-GMO-NL-2016-134 are expected to be as safe as and nutritionally equivalent to the
single maize events, the previously assessed maize subcombinations and the five-event stack maize
(Section 3.5.3). Therefore, the GMO Panel considers that post-market monitoring of food and feed from
the five-event stack maize and its subcombinations, as described in this application, is not necessary.
3.6.2. Post-market environmental monitoring
The objectives of a post-market environmental monitoring (PMEM) plan, according to Annex VII of
Directive 2001/18/EC, are: (1) to confirm that any assumption regarding the occurrence and impact of
potential adverse effects of the GMO, or its use, in the ERA are correct; and (2) to identify the
occurrence of adverse effects of the GMO, or its use, on human health or the environment that were
not anticipated in the ERA.
40 Dossier: Part II – Sections 4 and 6.
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Monitoring is related to risk management, and thus a final adoption of the PMEM plan falls outside
the mandate of EFSA. However, the GMO Panel gives its opinion on the scientific rationale of the PMEM
plan provided by the applicant (EFSA GMO Panel, 2011b).
As the ERA did not identify potential adverse environmental effects from the five-event stack maize,
no case-specific monitoring is required.
The PMEM plan proposed by the applicant for the five-event stack maize includes: (1) the
description of a monitoring approach involving operators (federations involved in import and
processing), reporting to the applicant, via a centralised system, any observed adverse effect(s) of
GMOs on human health and the environment; (2) a coordinating system established by EuropaBio for
the collection of information recorded by the various operators; and (3) the review of relevant
scientific publications retrieved from literature searches (Lecoq et al., 2007; Windels et al., 2008). The
applicant proposes to submit a PMEM report on an annual basis and a final report at the end of the
authorisation period.
The GMO Panel considers that the scope of the PMEM plan provided by the applicant is consistent
with the intended uses of the five-event stack maize. The GMO Panel agrees with the reporting
intervals proposed by the applicant in its PMEM plan. The PMEM plan and reporting intervals are in line
with the intended uses of the five-event stack maize and its subcombinations.
In the context of annual PMEM reports, the applicant could further fine–tune future literature
searches according to the GMO Panel recommendations given in Section 3.3.
3.6.3. Conclusion on post-market monitoring
No post market monitoring of food and feed is necessary. The scope of the PMEM plan provided by
the applicant and the reporting intervals are in line with the intended uses of maize
MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603.
4. Overall conclusions
The GMO Panel was asked to carry out a scientific assessment of maize MON 87427 9 MON 87460
9 MON 89034 9 MIR162 9 NK603 and subcombinations for import, processing and food and feed
uses in accordance with Regulation (EC) No 1829/2003.
No new information on the five single maize events MON 87427, MON 87460, MON 89034, MIR162
and NK603 that would lead to a modification of the original conclusions on their safety were identified.
The molecular characterisation, the comparative analysis (agronomic, phenotypic and compositional
characteristics) and the outcome of the toxicological, allergenicity and nutritional assessment indicate
that the combination of the single maize events and of the newly expressed proteins in the five-event
stack maize does not give rise to food/feed safety and nutritional concerns. The GMO Panel concludes
that the five-event stack maize, as described in this application, is as safe as and nutritionally
equivalent to its non-GM comparator and the non-GM reference varieties tested.
The GMO Panel concludes that there is a very low likelihood of environmental effects resulting from
the accidental release of viable grains from the five-event stack maize into the environment.
Since no new data on the eleven subcombinations previously assessed that would lead to a
modification of the original conclusions on their safety were identified, the GMO Panel considers that
its previous conclusions on these maize stacks remain valid. For the remaining 14 subcombinations
included in the scope of application EFSA-GMO-NL-2016-134, no information has been provided. The
GMO Panel assessed possible interactions between the events in the 14 subcombinations, and
concludes that these combinations of events MON 87427, MON 87460, MON 89034, MIR162 and
NK603 would not raise safety concerns. These subcombinations are therefore expected to be as safe
as and nutritionally equivalent to the maize single events, the previously assessed subcombinations
and the five-event stack maize.
Based on the relevant publications identified through the literature searches, the GMO Panel did not
identify any safety issues pertaining to the intended uses of maize MON 87427 9 MON 87460 9 MON
89034 9 MIR162 9 NK603 and its subcombinations. In the context of annual PMEM reports, the applicant
could further fine–tune future literature searches according to the GMO Panel recommendations.
In addition, the GMO Panel considered the additional unpublished studies listed in Appendix B. This
new information does not raise any concern for human and animal health and the environment
regarding the five-event stack maize and its subcombinations.
Given the absence of safety concerns for foods and feeds from the five-event stack maize and all
its subcombinations, the GMO Panel considers that post-market monitoring of these products is not
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necessary. The post-market environmental monitoring plan and reporting intervals are in line with the
intended uses of the five-event stack maize and its subcombinations.
In conclusion, the GMO Panel considers that maize MON 87427 9 MON 87460 9 MON 89034 9
MIR162 9 NK603 and its subcombinations, as described in this application, are as safe as the non-GM
comparator and the tested non-GM reference varieties with respect to potential effects on human and
animal health and the environment
Documentation as provided to EFSA
• Letter from the Competent Authority of Netherlands received on 03 November 2016 concerning a
request for authorisation of the placing on the market of maize MON87427 9 MON87460 9
MON89034 9 MIR162 9 NK603 (EFSA-GMO-NL-2016-134) submitted in accordance with
Regulation (EC) No 1829/2003 by Monsanto Europe S.A./N.V.
• Application EFSA-GMO-NL-2016-134 validated by EFSA, 19 January 2017
• Request for supplementary information to the applicant, 24 January 2017
• Receipt of supplementary information from the applicant, 30 January 2017
• Request for supplementary information to the applicant, 24 February 2017
• Request for supplementary information to the applicant, 12 April 2017
• Receipt of supplementary information from the applicant, 24 April 2017
• Request for supplementary information to the applicant, 06 June 2017
• Receipt of supplementary information from the applicant, 09 June 2017
• Request for supplementary information to the applicant, 06 July 2017
• Receipt of supplementary information from the applicant, 14 July 2017
• Receipt of supplementary information from the applicant, 07 August 2017
• Request for supplementary information to the applicant, 15 February 2018
• Request for supplementary information to the applicant, 23 March 2018
• Receipt of supplementary information from the applicant, 24 May 2018
• Request for supplementary information to the applicant, 18 June 2018
• Receipt of supplementary information from the applicant, 13 August 2018
• Request for supplementary information to the applicant, 15 October 2018
• Receipt of supplementary information from the applicant, 16 October 2018
• Request for supplementary information to the applicant, 08 November 2018
• Receipt of supplementary information from the applicant, 08 November 2018
• Receipt of supplementary information from the applicant, 16 November 2018
• Receipt of supplementary information from the applicant, 22 November 2018
• Request for supplementary information to the applicant, 21 December 2018
• Request for supplementary information to the applicant, 25 January 2019
• Request for supplementary information to the applicant, 07 February 2019
• Receipt of supplementary information from the applicant, 11 March 2019
• Receipt of supplementary information from the applicant, 19 March 2019
• Receipt of supplementary information from the applicant, 27 March 2019
• Request for supplementary information to the applicant, 24 April 2019
• Receipt of supplementary information from the applicant, 30 April 2019
• Receipt of supplementary information from the applicant, 08 May 2019
• Receipt of supplementary information from the applicant, 21 May 2019
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Abbreviations
ADF acid detergent fibre
bw body weight
CaMV cauliflower mosaic virus
CSPB cold shock protein B
CRM comparative relative maturity
CTP chloroplast transit peptide
ELISA enzyme-linked immunosorbent assay
EPSPS 5-enolpyruvylshikimate-3-phosphate synthase
ERA environmental risk assessment
FMV Figwort Mosaic Virus
fw fresh weight
GM genetically modified
GMO genetically modified organism
GMO Panel EFSA Panel on Genetically Modified Organisms
HGT horizontal gene transfer
HR homologous recombination
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IgE immunoglobulin E
LOQ limit of quantification
NDF neutral detergent fibre
NPTII neomycin phosphotransferase II protein
OECD Organisation for Economic Co-operation and Development
ORF open reading frame
PCR polymerase chain reaction
PMEM post-market environmental monitoring
PMI phosphomannose isomerase
T-DNA transfer-deoxyribonucleic acid
UTR untranslated region
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Appendix A – Protein expression data
Means, standard deviation and ranges of protein levels (lg/g dry weight) from maize MON
87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 (treated with glyphosate), MON 87427
(treated with glyphosate), MON 87460 (not treated), MON 89034 (not treated), MIR162 (not treated)
and NK603 (treated with glyphosate), from field trials performed in USA in 2014(a)
Protein Event(s)
Leaf
(V3-V4)
Root
(V3-V4)
Forage (R5) Grain (R6)
CP4
EPSPS(b)
MON 87427 3 MON 87460 3
MON 89034 3 MIR162 3
NK603
1,100(c)
180(d)
(810–1,400)(e)
340  54
(250–420)
210  68
(99–290)
15  2.2
(12–20)
MON 87427 800  92
(620–940)
240  47
(170–330)
150  57
(51–240)
7.3  1.3
(5.2–9.5)
NK603 280  56
(200–380)
130  25
(66–170)
66  26
(28–130)
9.7  1.9
(6.5–14)
CSPB MON 87427 3 MON 87460 3
MON 89034 3 MIR162 3
NK603
2.0  0.46
(1.3–3.3)
1.2  0.40
(0.57–2.1)
0.079  0.022
(0.054–0.13)
0.082  0.019
(0.056–0.12)
MON 87460 2.1  0.52
(1.1–2.8)
1.5  0.55
(0.35–2.2)
0.092  0.020
(0.061–0.14)
0.082  0.018
(0.060–0.12)
NPTII MON 87427 3 MON 87460 3
MON 89034 3 MIR162 3
NK603
4.7  0.99
(3.1–6.5)
0.86  0.14
(0.61–1.2)
0.18  0.054
(0.071–0.28)
0.0063  0.00091
(0.0055–0.0080)
MON 87460 4.3  1.1
(3.0–6.5)
0.91  0.22
(0.57–1.5)
0.19  0.046
(0.078–0.28)
0.006  0.00045
(0.0056–0.0065)
Cry1A.105 MON 87427 3 MON 87460 3
MON 89034 3 MIR162 3
NK603
850  350
(250–1,300)
61  11
(43–83)
26  6.4
(10–36)
8.1  3.5
(3.8–15)
MON 89034 880  220
(270–1,300)
70  15
(49–100)
26  6.6
(16–37)
7.2  3.7
(4.1–16)
Cry2Ab2 MON 87427 3 MON 87460 3
MON 89034 3 MIR162 3
NK603
170  46
(120–310)
160  37
(85–210)
34  8.7
(17–49)
1.6  0.40
(1.0–2.4)
MON 89034 150  25
(110–180)
160  44
(74–250)
28  5.8
(20–38)
1.9  0.39
(1.3–2.8)
Vip3Aa20 MON 87427 3 MON 87460 3
MON 89034 3 MIR162 3
NK603
130  35
(79–220)
50  7.8
(35–65)
69  20
(33–110)
38  6.2
(29–50)
MIR162 130  34
(74–200)
57  7.4
(44–68)
68  22
(44–120)
38  5.6
(29–49)
PMI MON 87427 3 MON 87460 3
MON 89034 3 MIR162 3
NK603
11  3.0
(6.9–17)
6.8  1.2
(4.5–9.6)
4.0  2.0
(0.90–9.7)
1.2  0.16
(0.94–1.5)
MIR162 11  2.3
(8.4–15)
7.2  1.5
(5.0–11)
3.6  1.3
(1.7–5.7)
1.4  0.30
(0.82–2.0)
(a): Number of sample is n = 19 or n = 20 except for: n = 18 for forage/R5 (for Cry1A.105 and Cry2Ab2 in MON 89034); n = 6
and n = 3 for grain/R6 (for NPTII in the five-event stack and MON 87460, respectively).
(b): EPSPS levels in the maize MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603 are a sum of two protein variants,
CP4 EPSPS (expressed in MON 87427 and NK603) and CP4 EPSPS L214P (expressed in NK603).
(c): Mean.
(d): Standard deviation.
(e): Range.
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Appendix B – List of additional studies performed by or on behalf of the
applicant with regard to the evaluation of the safety of maize
MON 87427 3 MON 87460 3 MON 89034 3 MIR162 3 NK603 for humans,
animal or the environment
Study
identification
Title
MSL0026336 Southern Blot Analyses to Confirm the Presence of MON 87427, MON 87460, MON 89034,
and NK603 in the Combined Trait Maize Product MON 87427 9 MON 87460 9 MON
89034 9 MIR162 9 NK603
MSL0026337 Southern Blot Analyses to Confirm the Presence of MIR162 in the Combined Trait Maize
Product MON 87427 9 MON 87460 9 MON 89034 9 MIR162 9 NK603
MSL0026638 Compositional Analyses of Maize Grain from MON 87427 9 MON 87460 9 MON 89034
9 MIR162 9 NK603 Grown in the United States in 2014
MSL0026879 Phenotypic Evaluation and Environmental Interactions of Maize MON 87427 9 MON
87460 9 MON 89034 9 MIR162 9 NK603 in 2014 U.S. Field Trials
MSL0026880 Phenotypic Evaluation of Maize MON 87427 9 MON 87460 9 MON
89034 9 MIR162 9 NK603 with Herbicide Treatment in 2014 U.S. Field Trials
MSL0027322 An Evaluation of the Potential for Interaction between MON 87460 and the Insecticidal Traits
in the Combined Maize Product MON 87427 9 MON 87460 9 MON
89034 9 MIR162 9 NK603 with Corn Earworm (Helicoverpa zea)
MSL0027523 Comparison of Lipid Transfer Protein (LTP) Expression Levels from MON 87427 9
MON 87460 9 MON 89034 9 MIR162 9 NK603 with Conventional Control Maize
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